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Research Portfolio Abstract 
 
Introduction:  This research portfolio set out to examine service user defined recovery 
in psychosis.  A systematic review was undertaken to examine the evidence-base for 
the effectiveness of psychosocial interventions on personal recovery, empowerment 
and other recovery-related outcomes.  An empirical study was conducted to examine 
the relationships between self-stigma, decisional capacity for treatment and personal 
recovery in service users with psychosis.     
 
Methods:  A review of published literature identified ten randomised controlled trials 
investigating the effects of psychosocial interventions on personal recovery.  A narrative 
synthesis was reported for findings relating to primary and secondary outcomes, and 
standardised effect sizes were calculated to quantify within-group change from pre-to 
post-intervention and follow-up.  Studies were assessed for risk of bias.  The empirical 
study recruited twenty-four participants with diagnoses of non-affective psychosis.  
Semi-structured interviews and self-report measures were administered to assess self-
stigma, decisional capacity for treatment, psychopathology, emotional distress and 
personal recovery.        
 
Results:  A small number of studies found that recovery-focused psychosocial 
interventions improved personal recovery.  There were more consistent effects on 
psychiatric symptoms, functioning and depression.  The empirical study found that self-
stigma and personal recovery were associated with each other.  Large effect sizes were 
found for the associations between self-stigma and symptoms.  These associations 
persisted when controlling for personal recovery scores.  Understanding of treatment 
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was predicted by excitement symptoms, but no other prediction model emerged for 
decisional capacity.   
 
Conclusion: Taken together, the systematic review and empirical project support 
service user definitions of recovery which highlight the role of psychosocial factors.  The 
systematic review found some evidence for the role of recovery-focused psychosocial 
interventions in improving personal recovery.  Further research is needed so that 
interventions specifically targeting the processes in personal recovery can be 
developed.  The findings from the empirical project suggested that interventions 
designed to overcome self-stigmatising beliefs and reduce emotional distress are likely 
to improve personal recovery outcomes in psychosis.  More research is needed to 
develop a broader conceptualisation of decisional capacity in psychosis, to support the 
active participation of service users in their recovery journey.   
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Purpose.  To examine the evidence-base for the effectiveness of psychosocial 
interventions in improving user-defined personal recovery and recovery related 
outcomes in psychosis. 
 
Method.  A systematic review of published literature was conducted.  Randomised 
controlled trials investigating the effects of psychosocial interventions on personal 
recovery were identified.  Studies were assessed for risk of bias.  Study findings 
regarding between-group differences at post-intervention and follow-up were 
summarised.  Standardised effect sizes were calculated to quantify the change within 
groups from baseline to post-intervention and from baseline to follow-up on the primary 
and secondary outcomes. 
 
Results.  Ten studies met inclusion criteria.  A small number of studies found that 
psychosocial interventions significantly improved personal recovery and empowerment 
outcomes compared to routine care.  Half of the studies found within-group 
improvement on personal recovery following the psychosocial intervention, with robust 
within group effects for individual cognitive therapy (CT).  There were more consistent 
effects of psychosocial interventions on the secondary outcomes e.g. psychiatric 
symptoms, functioning and depression.  The small number of studies and risk of bias 
suggest findings should be interpreted with caution. 
 
Conclusions.  Research into how interventions can improve personal recovery in 
psychosis is still in its infancy.  The current evidence signals that recovery-focused 
interventions may improve personal recovery, and may have more consistent effects on 
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recovery-related secondary outcomes.  Further research is needed so that interventions 
specifically targeting the processes in personal recovery can be developed.  
 
Practitioner points 
 The limited evidence available signals that recovery-focused psychosocial 
interventions can help to improve service user defined recovery. 
 
 Manualised cognitive therapy for psychosis, modified to address issues of 
internalised stigma, may have a more robust effect on personal recovery 
improvement than other psychosocial interventions, but further studies are 
needed to support this. 
 
 Measures of personal recovery should be used to track changes in the service 
user’s experience of recovery, to inform future care planning and to ultimately 






Recovery from severe mental illness is a complex process with ongoing debate 
regarding definitions of recovery (Schrank & Slade, 2007).  Until now, the ‘clinical 
recovery’ model of mental health care, with its focus on diagnostic classifications of 
symptoms, has dominated how individuals with psychosis have been understood and 
treated.  This approach emphasises the management of psychiatric symptoms and a 
return to ‘normal functioning’ (Davidson, O'Connell, Tondora, Lawless, & Evans, 2005).  
However, clinical definitions of recovery have been criticised for treating recovery as an 
endpoint, predicated on symptom remission (Davidson et al., 2005).  Furthermore, 
clinical diagnosis has been implicated in contributing to the stigma experienced by 
service users, and health professionals are at risk of compounding this by viewing 
service users as groups of psychiatric diagnoses rather than individuals (Corrigan, 
2007). 
 
In contrast, service users advocate that recovery involves overcoming psychological 
and social consequences of a mental health diagnosis, rather than reducing the 
symptoms of illness per se – an approach that has been defined as ‘personal recovery’ 
(Davidson et al., 2005; Schrank & Slade, 2007; Slade, 2009).  This conceptualisation of 
recovery, evolved from service user narratives, challenges the traditional clinical 
recovery model of care.  Given the uniqueness of recovery to each individual, there has 
been difficulty reaching a clear definition of personal recovery within the service user 
community (Leamy, Bird, Le Boutillier, Williams, & Slade, 2011).  However, reviews of 
service user narratives highlight common factors and values.  Personal recovery has 
been characterised as a journey (Leamy et al., 2011) that has a number of stages 
through which service users develop awareness and acceptance of their disorder 
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(Schrank & Slade, 2007).  A review of the personal recovery literature identified five 
processes as being integral to the recovery journey: connectedness; hope and 
optimism about the future; identity; meaning in life; and empowerment (Leamy et al., 
2011).  A subsequent review supplemented these processes with an additional 
dimension emphasising the struggles that are experienced in recovery, related to living 
with a mental health disorder, and likely impacted upon by social inequality (Stuart, 
Tansey, & Quayle, 2016).   
 
Empirical research has demonstrated that personal recovery is associated with self-
esteem, empowerment, social support and quality of life (Corrigan, Giffort, Rashid, 
Leary, & Okeke, 1999).  Furthermore, there is evidence that gaining control over 
psychiatric symptoms enhances personal recovery (Corrigan et al., 1999; Macpherson 
et al., 2015).  However, service users reported a greater level of consensus on a 
number of psychosocial factors essential for personal recovery, such as self-esteem 
and satisfaction with life, than on the management of symptoms (Law & Morrison, 
2014).  In contrast to clinical recovery, the personal recovery literature highlights that 
recovery, as defined by service users, can take place in the absence or presence of 
symptoms.     
 
Encouragingly, over recent years policy makers have endorsed the personal recovery 
approach and have called for mental health agencies to offer services that empower 
service users to take control of their lives and maximise their wellbeing (Macpherson et 
al., 2015; Schrank & Slade, 2007).  Despite this, psychosocial interventions for people 
with psychosis have predominantly been evaluated according to their effectiveness in 
producing symptomatic and functional change.  However, if recovery involves far more 
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than symptom remission and resolution of functional deficits, as indicated by the 
personal recovery literature, then these methods of evaluation are unlikely to go far 
enough to detect changes in outcomes that are valued by service users.  As others 
have pointed out (e.g. Bradstreet, 2016), continued reliance on clinical recovery 
outcomes poses a risk of service providers withdrawing interventions that give rise to 
meaningful change for service users but cannot be shown to produce symptomatic 
change, or may even result in service users facing early discharge from services when 
symptomatic recovery has been reached while other processes integral to personal 
recovery have not been addressed.  Thus, in order for service providers to align their 
services with the broader values of recovery that are important to service users, they 
may want to consider effectiveness according to personal recovery outcomes.  Shifting 
from service-imposed clinical recovery to user-defined personal recovery will likely 
require significant cultural change in mental health organisations (Schrank & Slade, 
2007). 
 
To facilitate this change, psychometric instruments have been developed and 
evaluated, often in consultation with service users, to measure personal recovery 
outcomes.  Reviews of these instruments have been published over recent years (e.g. 
Cavelti, Kvrgic, Beck, Kossowsky, & Vauth, 2012; Law, Morrison, Byrne, & Hodson, 
2012; Shanks et al., 2013; Sklar, Groessl, O'Connell, Davidson, & Aarons, 2013).  
Earlier instruments, such as the Recovery Assessment Scale (RAS; Giffort et al., 1995) 
were developed to understand and measure personal recovery across the spectrum of 
severe mental illness, however an instrument has now been developed specifically for 
personal recovery in psychosis (Questionnaire on the Process of Recovery, QPR; Neil 
at al., 2010).  Consequently, researchers have called for such measures to be used 
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routinely in the evaluation of psychosocial interventions (Andresen, Caputi, & Oades, 
2010; Macpherson et al., 2015; Neil et al., 2010).   
 
In summary, recovery from the perspective of service users, defined as personal 
recovery, encompasses a broad range of psychosocial factors not taken into account by 
clinical definitions of recovery.  Recognition of service users’ lived experiences of 
recovery and endorsement of psychosocial care in mental health policy has the 
potential to change the landscape of mental health care for service users with 
psychosis.  It seems timely to review the existing literature to establish what 
psychosocial interventions are effective in producing personal recovery outcomes that 
are of value to service users.  The present review aimed to address this gap in the 
research by asking the following research questions: 
 
1) Do recovery-focused psychosocial interventions improve user-defined recovery 
and empowerment for individuals with psychosis? 
 
2) Do recovery-focused psychosocial interventions improve secondary outcomes, 
including psychiatric symptoms, depression, anxiety, functioning and quality of 
life? 
 












An electronic search of the Cochrane Central Register of Controlled Trials (CENTRAL), 
EMBASE, OVID MEDLINE (R), PsycINFO and Web of Science databases was 
undertaken using the following terms: (psychosis OR schizophrenia OR schizotypal 
disorder OR schizoaffective disorder OR delusional disorder OR severe mental illness 
OR serious mental illness) AND (recovery OR “personal recovery” OR “consumer 
recovery” OR “mental health recovery”  OR “mental illness recovery”) AND (randomised 
controlled trial or randomized controlled trial).  The search was limited to studies listed 
since 1995 (the inception of the RAS personal recovery measure).  Searches were also 
run on the titles and abbreviations of the two personal recovery outcome measures of 
interest to this review: “Recovery Assessment Scale” OR “RAS” and “Questionnaire on 
the Process of Recovery” OR “QPR”.  The original citations for both outcome 
instruments were entered into the Google Scholar search engine to identify, and screen 
for eligibility, studies that had cited these measures.  Hand searches of the reference 
lists of included studies were performed to identify any further studies not returned in 
the electronic searches. 






1) Study design 
Studies were included if they were randomised controlled trials (RCTs), 
including cluster RCTs, reported in English language.  Blinded and non-blinded 




Studies were included if participants were adults and at least 50% of study 




Included studies reported outcomes for recovery-focused psychosocial 
interventions.  These included psychological therapy, skills training, education, 
psycho-education, peer support and family interventions.  Interventions 
delivered in individual, group, face-to-face or remote formats, and those that 







Studies had a comparison group that involved either treatment as usual (TAU), 
an alternative intervention, a placebo-type treatment (e.g. befriending), or 
placement on a waiting-list for the duration of the intervention. 
 
5) Outcome measures 
Studies included either the RAS or QPR as an outcome measure.  These 
instruments were selected based on findings from earlier systematic reviews 
which found them to be the most psychometrically valid and reliable outcome 
measures of personal recovery currently available, with the greatest 




Studies were excluded if the intervention being evaluated was pharmacological or was 
deemed to be predominantly sociological (e.g. employment or housing programmes).  
There were no limitations on the basis of drop-out, missing data, or length of follow-up, 
given the preliminary stage of this research. 
 
Pre-registration of review protocol 
The review protocol was published in January 2016 on the PROSPERO International 
Prospective Register of Systematic Reviews, Registration number: CRD42016032910 
(Lynch, 2016).   
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Data extraction and outcomes 
 
The Cochrane Collaboration Data Collection Form for Intervention Reviews: RCTs 
(Higgins & Green, 2011) was used to evaluate study eligibility and for data extraction 
from included studies (Appendix 3).  Reasons for studies excluded from the review 
were documented.  For included studies, information was extracted regarding the study 
location, characteristics of participants, types of interventions and comparison groups, 
outcome measures, length of follow-up, type of analysis and main study findings. 
Group means, standard deviations and number of participants at baseline, end of 
treatment and follow-up were extracted for all available outcomes relevant to the 
review.  Within-group effect sizes were calculated to indicate the magnitude of change 
observed from pre- to post-intervention and follow-up on each of the relevant outcomes 
using an online calculator, 
(http://campbellcollaboration.org/escalc/html/EffectSizeCalculator-SMD1.php).  Due to 
the heterogeneity of the interventions involved, effect sizes of between-group 
differences across studies on each of the outcomes of interest to this review were not 
analysed.  The magnitude of pre- to post-intervention and pre- to follow-up effects were 
considered according to Cohen’s criteria of small, medium and large effects of 0.2, 0.5 
and 0.8, respectively (Cohen, 1992).   
 
Risk of bias 
 
Methodological quality of the included studies was assessed using the Cochrane 
Collaboration Risk of Bias tool (Higgins & Green, 2011).  This assessment tool covers 
the domains of sequence generation, allocation concealment, blinding, selective 
outcome reporting, and incomplete outcome data.  The risk of bias for each domain was 
rated as high, low or unclear.  An unclear risk of bias rating was applied where there 
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was insufficient detail of procedures used to inform a judgement.  A second rater 
randomly selected and independently assessed for risk of bias 40% of the included 
studies.  Inter-rater reliability was calculated, Kappa = 0.659 (p < 0.001), suggesting a 





Study selection, design and characteristics 
 
The search strategy is outlined in Figure 1. After title, abstract and full text review, ten 
randomised controlled trials were identified as being eligible for inclusion in the review. 
The reasons for studies excluded following full-text review (n=119) are documented in 
Appendix 4.  Table 1 shows characteristics and demographics of the included studies.  
Studies were published between 2009 and 2016.  Three studies took place in the 
United Kingdom, two in the United States of America, and one each in Canada, 
Sweden, Switzerland, Denmark and Germany.  All studies were RCTs; one (Slade et 
al., 2015) was a cluster RCT evaluating the effect of a psychosocial intervention 
delivered at team level, and two studies (Morrison et al., 2016; Schnackenberg, 
Fleming, & Martin, 2016) were described as pilot RCTs to determine the feasibility of 
the psychosocial interventions being evaluated.  Seven studies used diagnostic criteria 
to confirm participants’ diagnoses at trial entry; four studies used ICD-10 and three 
studies used DSM-IV.  The remaining three studies did not report the use of any 
diagnostic criteria.   Sample size of the studies varied from 22 to 403 participants, with a 
total of n=935 participants, including 463 participants in the intervention groups and 442 
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measure did not meet 
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Duplicate/secondary 
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Other reason (n=3) 
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TAU alone 42 42 
(11) 
16/26 NR 42 42  
(9) 
17/25 NR None 3  
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not-for-profit 
integrated health 
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responding to a 
study invitation 



















Reported only for sample as a whole: 
Mean age (SD): 44.2 (9.8) 
Gender (F/M):17/13 
Diagnoses: 
Schizophrenia spectrum disorder, n=15 (50%); 
Bipolar disorder, n=11 (37%) 
Depression, n=3 (10%) 
3  6  
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Note: ACT, Assertive Community Treatment; BPRS-E, Brief Psychiatric Rating Scale - Expanded; CMHT, Community Mental Health Team; CT, Cognitive Therapy; DSM-IV, 
Diagnostic and Statistical Manual for Mental Disorders – Fourth Edition; EFC, Experience-Focused Counselling; EIS, Early Intervention Service; ICD-10, International Classification 
of Diseases – Tenth Revision; IMR, Illness Management and Recovery; ISMI-R, Internalised Stigma for Mental Illness Scale – Revised; GSD-SZ, Guided Self-Determination for 
Schizophrenia; TAU, Treatment as usual; MHPs, Mental Health Practitioners; NHS, National Health Service; NR, Not reported; PtR, Pathways to Recovery Workbook; RW, 







All studies reported on individual or group interventions provided in outpatient settings.    
Four studies involved psychosocial interventions delivered in a group format according 
to manualised treatment programmes.  In three studies (Barbic, Krupa, & Armstrong, 
2009; Fardig, Lewander, Melin, Folke, & Fredriksson, 2011; Salyers et al., 2014), the 
treatment manuals had been published previously.  The Illness Management and 
Recovery (IMR) programme was evaluated in two studies (Fardig et al., 2011; Salyers 
et al., 2014), the Recovery Workbook (RW) programme in another study (Barbic et al., 
2009) and the Pathways to Recovery (PtR) programme in the study that used a non-
published manual (Green, Janoff, Yarborough, & Paulson, 2013).  Group sizes ranged 
from n=3 to 9 participants.  All group interventions were delivered during weekly 
sessions, with durations ranging from 1 to 2 hours.  Number of group sessions offered 
across studies ranged from 10 to 40 sessions.  Both IMR programmes were completed 
over 9 months, whereas the RW and PtR programmes were delivered over periods of 
12 weeks and 10 weeks, respectively.  All group interventions were co-facilitated.  In 
two studies (Barbic et al., 2009; Green et al., 2013), at least one of the group facilitators 
was a member of the research team, and in one of these studies (Green et al., 2013) a 
service user was a co-facilitator.  In Fardig et al. (2011), co-facilitators were clinicians 
recruited for the study due to their interest in IMR, and in Salyers et al. (2014) the co-
facilitators were psychologists or masters-level clinician alongside doctoral psychology 
students.     
 
Group interventions offered a mix of psychoeducation, group discussion and practice of 
new skills.  All group interventions involved setting personal goals, learning how to 
manage stress and building social support.  The RW and IMR studies also supported 
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participants to develop a greater understanding of their mental health condition and 
working with the mental health system, while the IMR studies expanded their focus to 
the effective use of anti-psychotic medications, coping with symptoms and relapse 
prevention.  Most group interventions used homework assignments to enhance 
learning.  Participants in the IMR and RW groups received treatment as usual (TAU) in 
addition to the group interventions.     
 
Six interventions were delivered in an individual format with a range of 10 to 30 
sessions offered across studies.  Sessions typically lasted 1 hour per week, with the 
intervention period ranging from 4 to 12 months.  Two studies evaluated the effects of 
individual cognitive therapy (CT) on personal recovery.  In both studies, CT 
interventions were delivered via a manualised approach (Morrison, 2001).  Therapists 
delivering interventions had prior training in CT, with trial specific training, and had 
regular supervision throughout the trials.  Therapists’ fidelity to protocol was evaluated 
in one study (Morrison et al., 2014) through audio recording of sessions and 
independent rating using the Cognitive Therapy Scale-Revised (CTS-R).  One study 
evaluated an Experience-Focused Counselling (EFC) intervention whereby mental 
health practitioners were trained to work collaboratively with participants to develop an 
understanding of voice hearing experiences in the context of life experiences.  Another 
study examined the effects of an individual Guided Self-Determination for 
Schizophrenia (GSD-SZ) intervention which involved mental health practitioners being 
trained to help participants develop skills in shared decision making and problem 
solving.         





Eight studies compared intervention effects to control conditions where participants 
received TAU.  TAU was offered on its own in most studies except for the two CT 
studies where it was supplemented by regular monitoring.  The authors argued that 
TAU plus monitoring was superior to TAU alone because participants received benefits 
from a supportive and non-judgemental therapeutic relationship and signposting to 
appropriate services if necessary.  There was variance across and within studies on 
components of TAU.  In one study (Morrison et al., 2014) participants referred from 
Early Intervention (EI) services were likely to have regular contact with a care 
coordinator and access to other psychosocial interventions such as family work, whilst 
participants from other community services were likely to have less consistent care 
coordinator contact and limited access to other mental health professionals.  Other 
studies indicated that TAU could involve medication, cognitive behavioural therapy 
(CBT), psychoeducation and social skills training.  Only one study evaluated 
intervention effects against an active treatment control group.  This involved control 
participants receiving a problem solving intervention with the same format, number, 
frequency and duration of sessions as the experimental group.  The final study used a 





Personal recovery was included as a primary outcome in three studies (Green et al., 
2013; Schnackenberg et al., 2016; Slade et al., 2015), a secondary outcome in a further 
three studies (Jorgensen et al., 2015; Morrison et al., 2016; Morrison et al., 2014) and 
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not stated as a primary or secondary outcome in the remaining four studies.  No studies 
indicated measurement of personal recovery as a mediating or moderating variable.     
 
Six studies measured participants’ perception of recovery using RAS.  Five studies 
analysed RAS total scores, while one study (Huguelet et al., 2011) reported only 
individual scores yielded from each of the five RAS domains: personal confidence and 
hope, willingness to ask for help, reliance on others, not dominated by symptoms, and 
goal and success orientation.  Of the five studies that used RAS total scores, all but one 
(Fardig et al., 2011) analysed and reported the individual domain scores too.  The 
remaining four studies used the QPR in their outcome battery.   
 
Finally, two studies measured participants own judgements of empowerment using the 
Mental Health Confidence Scale (MHCS; Carpinello et al., 2000) and the Empowerment 
Scale (EmS; Rogers et al., 1997). 
  
Secondary outcomes 
Eight studies measured change in psychiatric symptoms over time.  All measures were 
interviewer-rated with assessment of recent symptoms by semi-structured interview.  
The Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987) was used in the 
majority of studies (n=5).  Other studies used a modified version of the Psychosis 
Evaluation Tool for Common Use by Caregivers (PECC; De Hert et al., 2002) (n=1), the 
Brief Psychiatric Rating Scale (BPRS; Overall & Gorham, 1962) (n=1), and the Brief 
Psychiatric Rating Scale – Expanded Version (BPRS-E; Lukoff et al., 1986) (n=1).  Only 
two studies (Morrison et al., 2016; Morrison et al., 2014)  measured depression and 
anxiety.  Three studies measured interviewer-rated changes in general functioning 
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using the Global Assessment of Functioning Scale (GAF; Endicott et al., 1976), while 
one study measured social functioning using the interviewer-rated Personal and Social 
Performance Scale (PSP; Morosini et al., 2000).  Six studies measured changes in self-
reported quality of life using a range of measures: The Quality of Life Index, General 
Version (QOLI; Ferrans & Powers, 1985) (n=1); the Manchester Short Assessment of 
Quality of Life (MANSA; Priebe et al., 1999) (n=2); the World Health Organisation 
Quality of Life Instrument (WHOQOL-BREF; The WHOQOL Group, 1998) (n=1); and 
the Wisconsin Quality of Life Index (W-QLI; Becker et al., 1993) (n=1).  A further study 
used the interviewer-rated Quality of Life Scale (QLS; Bilker et al., 2003).   
 
Follow-up 
Nine studies examined the effectiveness of the psychosocial intervention by measuring 
outcomes immediately following its completion (i.e. post-intervention).  Post-intervention 
time points across studies ranged from three to 12 months.  Six studies investigated 
whether post-intervention effects had been sustained by measuring outcomes at follow-
up points ranging from three to 12 months after post-intervention.  One study, in which 
the intervention was a spiritual assessment followed by supervision of the psychiatrist 
providing clinical care to the participant, did not measure outcomes immediately 
following completion of the assessment, but after a period of three months and there 
was no further follow-up.    
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Risk of bias 
Risk of bias ratings for individual studies are shown in Table 2.  Ratings recorded by the 
primary author (HL) can be found in Appendix 4.  The majority of studies (n=6) 
described adequate methods of randomisation to treatment groups.  Not all studies 
described methods to ensure allocation was concealed to study personnel, so it was 
unclear if these studies were affected by selection bias.  Performance bias may have 
influenced an overestimation of treatment effects in all studies because, even when 
studies followed adequate procedures to conceal group allocation at the point of 
randomisation, the nature of participating in a psychosocial intervention revealed 
allocation to both the intervention providers and participants.  Although outcomes were 
assessed by blind raters in the majority of studies (n=6), only two studies reported 
methods to prevent blind breaks and procedures for remedial action when they 
occurred (Morrison et al., 2016; Morrison et al., 2014).  There was a high risk of 
detection bias in four studies where treatment allocation was known to raters 
(Jorgensen et al., 2015; Schnackenberg et al., 2016) (Jorgensen et al., 2015; 
Schnackenberg et al., 2016; Slade et al., 2015) or blinding of raters was not reported 
(Green et al., 2013).  There was a threat to attrition bias in four studies where the loss 
to follow-up rate exceeded 25% (Morrison et al., 2014; Salyers et al., 2014; 
Schnackenberg et al., 2016; Slade et al., 2015), and it was unclear if this was the case 
for two studies where missing data and attrition was not explicitly reported.  The 
majority of studies (n=6), reported using intention-to-treat analyses.  Finally, there was a 
high risk of selective reporting bias in two studies (Green et al., 2013; Schnackenberg 
et al., 2016) where published reports omitted data on some of the pre-specified 
outcomes, and the effect of selective reporting on results was unclear in a further five 
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studies (Barbic et al., 2009; Fardig et al., 2011; Huguelet et al., 2011; Morrison et al., 
2016; Salyers et al., 2014) where there was no pre-published protocol.   
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Barbic et al. 
2009 
 
Unclear Unclear High Unclear Unclear Unclear Unclear 
Fardig et al. 
2011 
Low Unclear High Unclear Low Unclear Unclear 
Huguelet et al. 
2011 
 
Low Unclear High Unclear Unclear Unclear Unclear 
Green et al. 
2013 
Unclear Unclear High High Unclear High Unclear 
Morrison et al. 
2014 
 
Low Low High Low High Low Unclear 
Salyers et al. 
2014 
 
Unclear Unclear Unclear Unclear High Unclear Unclear 
Jorgensen et al. 
2015 
 
Low Low High High Low Low Unclear 
Slade et al. 
2015 
Low Low High High High Low Unclear 
Morrison et al. 
2016 
 




Unclear Unclear High High High High Unclear 
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Effectiveness of interventions 
 
Table 3 details the pre-to post-intervention and pre-to follow-up effect sizes for each 
available outcome of interest to the review, alongside a summary of key findings from 
each study, including between-group differences over time as reported by study 




Effect sizes representing change in personal recovery total scores within groups from 
pre-to post-intervention were reported for six studies (Barbic et al., 2009; Fardig et al., 
2011; Morrison et al., 2016; Morrison et al., 2014; Salyers et al., 2014; Slade et al., 
2015).  Intervention participants demonstrated improvement in overall personal 
recovery from pre-to post intervention in all but one study (Salyers et al., 2014).  
Receipt of individualised, manualised, psychosis-specific CT was associated with the 
greatest improvement in personal recovery.  In the standard CT for psychosis study, 
there was moderate improvement (d=0.51) at post-intervention, large improvement 
(d=1.10) at 6 month follow-up, with a large effect sustained (d=0.81) at nine-month 
follow-up (Morrison et al., 2014).  When CT was adapted to address high levels of 
internalised stigma, there was a large effect of the intervention at post-intervention 
(d=1.33) and three months later (d=1.15).  Control participants in this study, who 
received TAU plus monitoring, did not show any improvement in overall personal 
recovery post-intervention and a small improvement three months later.     
 
A further three studies showed small pre-to post-intervention improvements in overall 
personal recovery (Barbic et al., 2009; Fardig et al., 2011; Slade et al., 2015).  Control 
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participants in these studies (REFOCUS and IMR) also showed small improvements, 
while those in the RW study had a small deterioration in post-intervention personal 
recovery scores.  It was only possible to assess the longevity of personal recovery 
outcomes in the IMR study because the others did not have further follow-ups.  When 
outcomes were assessed a year later (after post-intervention), there was a moderate 
improvement for the IMR group while the improvement had become almost negligible 
for the TAU controls.  Interestingly, the second IMR group study (Salyers et al., 2014) 
failed to demonstrate any effect on personal recovery total scores for the intervention 
group at post-intervention, or at a follow-up assessment nine months later.  On the 
other hand, control participants who took part in a problem solving group showed 
improvement of a small magnitude which was maintained at nine-month follow-up.      
 
Three studies reported significant differences between intervention and TAU control 
groups in overall personal recovery (Barbic et al., 2009; Green et al., 2013; Morrison et 
al., 2016).  In particular, the RW and PtR groups led to greater judgements of personal 
recovery over time than TAU, while individualised CT for internalised stigma led to 
improvements in favour of the CT group at the four-month post-intervention but not at a 
follow-up 3 months later.  A fourth study (Huguelet et al., 2011) found a significant 
difference between groups in the domain ‘willingness to ask for help’, with participants 
who had received a spiritual assessment more willing to ask for help three months later 
than TAU controls.  
 
Empowerment 
Changes in participants’ perceptions of empowerment were measured in two studies.  
The 12-week recovery workbook group led to a large improvement (d=-4.63) in 
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empowerment, while TAU controls only had a small improvement (d=-0.27).  The one-
year REFOCUS intervention led to a small increase in empowerment (d=0.13), with a 
slight increase (d=0.06) for TAU controls.  Sustainability of effects could not be 
evaluated as neither study included a follow-up.  Only the RW study found a significant 
difference between groups over time with group participants reporting a significantly 




Within-group effect sizes were calculated for six of the eight studies that measured 
severity of psychiatric symptoms, while two studies did not report raw scores to allow 
for calculation.  Five studies found that psychosocial interventions reduced total 
psychiatric symptom severity scores at post-intervention, while one study found that 
total symptoms worsened three months after a spiritual assessment had been carried 
out.  Individual CT delivered over nine months led to a large reduction (d=-0.86) in 
psychiatric symptom severity at post-intervention.  Moreover, the large effect was 
sustained at further follow-ups of six and nine months.  In comparison, control 
participants who received TAU plus monitoring had a moderate improvement (d=-0.75) 
at post-intervention, which reduced to small improvements at three, six, and nine-month 
follow-ups.  Individual EFC delivered over 11 months also resulted in a large 
improvement (d=-0.91) in psychiatric symptom severity for the intervention group, 
whereas there was slight deterioration for TAU controls.  Another large improvement 
(d=-0.88) was found for an IMR group, which lowered to a moderate effect (d=-0.73) 
one year later (Fardig et al., 2011).  TAU participants in this study demonstrated only a 
small improvement (d=-0.20) in psychiatric symptom severity at post-intervention, 
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followed by a small deterioration (d=0.13) one year later.  Small improvements were 
found for the other IMR group, which converted to a large improvement (d=-0.80) at a 
follow-up 9 months later (Salyers et al., 2014).  In comparison, control participants who 
took part in a problem solving group showed moderate improvement (d=-0.63) in 
psychiatric symptoms at post-intervention; an outcome that was maintained at follow-
up.  In the team-level REFOCUS intervention, there was a small improvement (d=-0.24) 
in psychiatric symptom severity for the intervention group at post-intervention, and there 
was also a small improvement to a lesser degree (d=-0.06) for the TAU controls.  
Participants who took part in a spiritual assessment had a small deterioration (d=0.13) 
in psychiatric symptom severity at 3 month follow-up, and this was also the case for the 
TAU controls (d=0.25).  
 
Four studies reported significant group differences regarding severity of psychiatric 
symptoms.  Specifically, participants who received individual CT for psychosis 
(Morrison et al., 2014), individual GSD-SZ (Jorgensen et al., 2015), and one IMR group 
(Fardig et al., 2011) were found to have significantly reduced total severity scores 
compared to TAU at post-intervention and further follow-ups ranging from 6 to 12 
months.  Individual EFC led to a significant difference between groups in favour of the 
intervention only for the psychosis subscale.  Although there were no between-group 
differences in the second IMR study, both the intervention group and the problem 
solving control group showed significant improvement (d>0.5) in psychiatric symptoms 
over time (Salyers et al., 2014).  





Depression and anxiety 
Two studies examined the effects of individual CT on severity of depression and anxiety 
symptoms.  Intervention groups reported moderate to large improvements in depression 
severity from baseline to post-intervention and follow-up.  Those who received TAU had 
small to moderate improvements over these time points.   Regarding symptoms of 
social anxiety, small to moderate improvements were found for intervention groups in 
both studies at post-intervention and follow-up.  TAU groups in both studies had small 
improvements at post-intervention, which was maintained after 3 months for TAU 
participants in the CT for internalised stigma trial, but not for TAU participants in the 
standard CT trial.         
 
When group comparisons were considered, only CT modified to address internalised 
stigma led to a significant difference in depression scores in favour of the intervention 
over TAU at post-intervention; an effect that was lost by a 3-month follow-up.   Neither 
study found significant differences between groups in levels of social anxiety.  
  
Functioning 
Four studies measured changes in functioning and it was possible to calculate within-
group effect sizes for all but one study (Jorgensen et al., 2015).  CT for psychosis 
resulted in moderate improvement (d=0.54) in personal and social functioning at post-
intervention, while TAU had small to moderate improvement (d=0.43).  Moderate 
improvements were maintained for CT participants at further follow-ups of 3, 6 and 9 
months, while control participants had only small improvements at these time points.  
The REFOCUS intervention led to a small improvement in global functioning, while 
there was no change for TAU controls.  Finally, a spiritual assessment had no effect on 
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global functioning when it was assessed 3 months later, while those who received TAU 
had a slight deterioration in global functioning.   
 
Three studies reported significant group differences concerning functioning.  
Individual CT resulted in significantly improved personal and social functioning 
compared to TAU, which was sustained at 9-month follow-up.  The REFOCUS 
intervention led to significantly better global functioning than TAU at post-intervention.  
Finally, the GSD-SZ participants showed significantly better functioning over time than 
TAU on the GAF symptom subscale, but not the function subscale.    
 
Quality of life 
Within-group effect sizes for five of the six studies that measured quality of life are 
displayed in Table 2.  Small pre-post improvements were found for the RW, REFOCUS 
intervention and both IMR trials.  In addition, the spiritual assessment resulted in a 
small improvement only on the social domain of quality of life, but this was also the 
case for TAU controls.  An active PS control group fared better on quality of life at post-
intervention than the IMR group with mean scores approaching the moderate range 
(d=-0.48).  Both IMR and PS control groups maintained small improvements at follow-
up 9 months later.  The other IMR trial found that small treatment effects were not 
maintained one year later (Fardig et al., 2011).    
 
No studies found significant group differences on quality of life.  When IMR was 
evaluated against a problem solving intervention both groups improved significantly 





The published reports for four studies failed to mention the occurrence or absence of 
adverse events during the trials (Barbic et al., 2009; Fardig et al., 2011; Green et al., 
2013; Salyers et al., 2014).  For the other six studies, adverse events affected 1 to 10% 
of participants, including compulsory and voluntary admissions to hospital, overdose 
attempts and deaths.  In most cases these events were deemed not to be linked to trial 
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This review examined the degree to which psychosocial interventions are effective in 
improving service user defined recovery and empowerment for people with psychosis.  
The review specified a priori that included studies would be limited to those that had 
assessed personal recovery using reliable and valid psychometric measures, 
developed in collaboration with service users.  To our knowledge, this is the first review 
of its kind.  A secondary aim was to evaluate the effectiveness of psychosocial 
interventions on other important outcomes that may be linked to personal recovery, 
including psychiatric symptoms, depression, anxiety, functioning and quality of life. 
 
A systematic search of the literature identified a small number of RCTs (n=10) that had 
evaluated the effectiveness of psychosocial interventions on the personal recovery of 
service users, with limited evidence that psychosocial interventions improved personal 
recovery (n=3 studies) and empowerment (n=1 study) outcomes compared to routine 
care.  When within-group pre-post effects were considered, large improvements in 
personal recovery were found following individual CT (n=2 studies), while small 
improvements were found for other recovery-focused psychosocial interventions (n=3 
studies).  The RW and the REFOCUS intervention led to very large and small 
improvements, respectively, in participants’ perceptions of empowerment. 
 
In relation to the secondary outcomes, significant group differences were found 
indicating that recovery-focused psychosocial interventions performed significantly 
better than control comparisons at improving psychiatric symptoms (n=4 studies), 
functioning (n=3 studies), and depression (n=1 study).  When pre-post effects were 
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considered, there was evidence that psychosocial interventions were effective at 
improving psychiatric symptoms, depression, social anxiety, quality of life, and 
functioning.  The most robust effects were found for psychiatric symptoms, where large 
improvements were found for group IMR (n=1 study), individual CT for psychosis (n=1 
study), and individual EFC (n=1 study).  This was followed by moderate to large 
improvements in depression and social anxiety for individual CT (n=2 studies).  Finally, 
psychosocial interventions resulted in small to moderate improvement in functioning 
(n=2 studies) and small improvements in quality of life (n=5 studies).   
 
Limitations of included studies 
 
There were a number of limitations within the included studies that were likely to have 
introduced bias, thus findings should be interpreted with caution.  Most studies did not 
find significant differences between groups on the primary outcome of personal 
recovery or several of the secondary outcomes.  Small sample sizes within studies may 
have resulted in insufficient power to detect intervention effects, particularly if the 
effects were small.  This was likely to be a more significant problem for studies where 
the drop-out rate was greater than 25%.  Only a minority of studies published details 
regarding a priori statistical power calculations that anticipated drop-out.  In addition, 
very few studies followed procedures to ensure fidelity to the intervention protocols, so 
it is possible that the implementation of the psychosocial interventions may have 
compromised their effectiveness.   
 
It is also possible that where significant effects were reported, these may have been 
better ascribed to the common factors associated with taking part in a structured, 
therapeutic intervention rather than the unique psychosocial intervention per se.  The 
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majority of included studies were vulnerable to this bias having evaluated their 
psychosocial interventions against routine care, and therefore the common therapeutic 
factors which may have benefitted the intervention groups were not controlled for in 
comparison groups.  Indeed, there were no differences found between groups in the 
one study that did use an active control comparison group (Salyers et al., 2014).   
 
Studies were unable to blind participants to treatment allocation making them 
vulnerable to performance bias, which also leads to overestimation of effect sizes 
(Higgins & Green, 2011).  The risk of bias ratings showed a high number of unclear or 
high risk of bias ratings, suggesting that the overall study quality was fairly low.  All 
studies used outpatient samples limiting the generalisability of findings to patients 
receiving acute care in inpatient environments.  Generalisability was also compromised 
by high refusal rates for study participation, thus conclusions can only be drawn about 
individuals who engaged with the intervention.  Finally, there was limited evidence 
available regarding longer-term effects of psychosocial interventions on outcomes, due 
to the lack of adequate follow-up.     
 
Limitations of review 
 
There were several limitations to the review itself.  Only a small number of studies met 
inclusion criteria, and only two studies evaluated the same type of intervention, so 
meta-analysis was not performed.  Only published studies were included which puts the 
review at risk of overestimating the effects of the interventions (Higgins & Green, 2011).  
Furthermore, results are based on data available in the published study reports, 
therefore missing data may have biased the review findings.  Review inclusion criteria 
limited sampling to participants with diagnoses of schizophrenia, schizoaffective 
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disorder and other non-affective psychoses, limiting the generalisability of the findings 
beyond the study population and preventing a transdiagnostic approach (Barlow, Allen, 
& Choate, 2004).  Finally, measurement of personal recovery may have introduced 
bias: only the QPR was designed specifically for a psychosis population, so it is 
possible that the RAS may lack sensitivity to detect changes in personal recovery in the 
study population.  These issues highlight that more research is needed to examine if 




This review highlights that research into personal recovery in psychosis remains at a 
preliminary stage.  The findings from the review signal that current recovery-focused 
psychosocial interventions may have some benefit on improving the personal recovery 
outcomes of service users with psychosis.  Interestingly, these interventions had more 
consistent effects on secondary outcomes related to recovery.  In particular, there was 
support from both within-group effect sizes and significant group comparisons to 
suggest that recovery-focused interventions may be effective at improving psychiatric 
symptoms, functioning and depression.  These findings have to be interpreted 
cautiously given the context of the risk of bias ratings which indicated that study quality 
was compromised by a high number of unclear or high risk of bias ratings.  
 
Only a minority of studies found significant group differences on personal recovery.  
This raises the question of whether recovery-focused interventions are targeted towards 
personal recovery.  Examination of within-group effect sizes suggested that at least half 
of the interventions influenced improvement in personal recovery, so it could simply be 
that treatment gains were as beneficial as those resulting from routine care.  It is 
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notable that routine care, as described by study authors, often included access to other 
psychosocial interventions which may have also promoted personal recovery and 
confounded the results.  Alternatively, it is possible that the personal recovery 
measures used in the studies, although expected to have high acceptability to service 
users, may be insufficient to detect changes in personal recovery.  It has been noted 
that personal recovery is an idiosyncratic process (Leamy et al., 2011), presenting a 
measurement challenge.  Another possibility is that psychosocial interventions did not 
have differential benefits over routine care because personal recovery is a dynamic 
process i.e. change occurs in different domains over a longer recovery journey.  In this 
formulation, changes in psychiatric symptoms, depression, and functioning represent 
incremental steps, giving rise to later changes in recovery and empowerment.  Thus 
short durations of study follow-up in the studies would not be sensitive to change.  This 
is consistent with an emerging literature conceptualising recovery as a multi-stage 
journey (Leamy et al., 2011; Schrank & Slade, 2007).     
 
Implications for research 
 
Future research is warranted to establish what components of psychosocial 
interventions facilitate improvement at different points in the recovery journey.  This 
“what works for whom” approach enables development of more targeted and 
personalised interventions varying according to service users’ individual needs.  
Conceptualising recovery as a dynamic process suggests future studies would benefit 
from outcome measurement at more frequent time points and include longer periods of 
follow-up.  A number of studies were excluded from the review because their outcome 
assessments did not include personal recovery measures developed in consultation 
with service users.  The paucity of valid, reliable and acceptable measures of personal 
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recovery suggest more effort is required in establishing fit-for-purpose measures.  
Future studies should also incorporate larger sample sizes, active treatment control 
groups and measures to counter the effects of bias.     
 
Implications for services 
 
We will only truly know if recovery-oriented services are effective if they are evaluated 
in accordance with service user definitions of recovery.  Going forward, personal 
recovery measures should be considered mandatory when evaluating interventions in 
research and clinical practice.  If interventions can be shown to produce outcomes that 
are valuable to service users, then this is likely to enhance service user engagement 
(Neil et al., 2010), as well as contributing to the evidence base.   
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Objectives.  To improve our understanding of the factors that promote personal 
recovery examining the relationships between self-stigma, symptomatic recovery, 
personal recovery and decisional capacity for treatment decisions in psychosis. 
 
Design.  A cross-sectional study was conducted to examine the relationships 
between study variables. 
 
Methods.  Twenty-four participants meeting criteria for schizophrenia, 
schizoaffective disorder or delusional disorder completed self-report measures of 
self-stigma, personal recovery and symptoms of emotional distress, as well as two 
semi-structured interviews assessing psychopathology and decisional capacity for 
treatment decisions.  Correlational analyses were used to examine associations 
between the study variables.  Linear regression analyses were conducted to 
examine the prediction of significant correlates on the understanding, appreciation 
and reasoning domains of decisional capacity. 
 
Results.  Self-stigma was positively associated with negative symptoms and 
emotional distress, whereas it was negatively associated with personal recovery and 
the reasoning domain of decisional capacity.  Regression analysis indicated that 
excitement predicted appreciation of disorder and treatment.   
 
Conclusions.  The findings suggest that interventions aimed at promoting recovery 
from psychosis should target self-stigmatising beliefs and the role of emotion.  The 
findings between excitement and reasoning may have implications for service 
engagement, although more research is needed to develop our understanding of the 
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psychological factors that are associated with decision-making, and new fit-for-
purpose measures need to be developed.   
 
Practitioner points 
 Higher levels of self-stigma were significantly associated with poorer 
personal recovery, greater negative symptoms and increased emotional 
distress.  Interventions that address self-stigmatising beliefs and the role of 
emotion are likely to promote recovery from psychosis.  
 
 More research is needed to identify the psychological factors that are likely 







Recent policy developments initiated a drive to improve psychosocial care for 
individuals with mental health disorders.  This shifts the focus from the dominant 
‘clinical recovery’ service model, characterised by medicalised and paternalistic 
care, to a ‘personal recovery’ model that empowers service users.  If this change is 
to be realised, mental health services will likely have to re-evaluate practices that 
disempower service users.  For service users with diagnoses of psychosis, coercive 
practices regarding care and treatment are not uncommon (Kinderman, 2014).  
Reassigning power to service users in decisions about their care and treatment is 
consistent with modern conceptualisations of personal recovery.  To date, there has 
been little psychological research regarding service users’ decisional capacity for 
treatment decisions, yet we need to understand the psychological factors that may 
promote or impede decisional capacity if service providers are to support their 
service users’ autonomy.  Qualitative studies implicate self-stigma as having 
negative consequences for service users’ involvement in treatment decisions.  
Given associations identified between self-stigma and markers of recovery from 
severe mental illness, self-stigma and personal recovery may influence decisional 
capacity for treatment decisions in psychosis.  This has yet to be subjected to 
empirical investigation.    
    
Personal recovery, evolved from the service user movement, advocates that service 
users with psychosis can progress towards living a meaningful life, even when 
psychiatric symptoms persist (Davidson, O'Connell, Tondora, Lawless, & Evans, 
2005).  Therefore, symptom reduction need not be the focus of recovery-oriented 
care.  This challenges the traditional clinical recovery perspective which primarily 
seeks to achieve symptom remission whilst also resolving deficits in functioning 
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(Davidson et al., 2005).  Service users agreed that management of symptoms is just 
one component contributing to a myriad of psychosocial factors considered essential 
for personal recovery (Law & Morrison, 2014).  Empirical research supports a role 
for psychiatric symptoms in both clinical and personal recovery (Morrison et al., 
2013), but symptom remission alone may not encapsulate recovery from psychosis.  
Indeed, personal recovery has been described as a journey with processes of 
developing awareness and acceptance of the mental health disorder, hope about 
the future, redefining the self, and becoming empowered as an active agent in one’s 
life (Leamy, Bird, Le Boutillier, Williams, & Slade, 2011; Schrank & Slade, 2007).    
 
Research suggests that endorsement of stigmatising beliefs about mental illness 
may act as a psychological barrier to personal recovery.  Self-stigma denotes 
individuals’ internalised negative beliefs, attitudes or expectations about their mental 
health disorder, based on public stereotypes of mental illness (Corrigan, Giffort, 
Rashid, Leary, & Okeke, 1999).  Stereotypes include perceptions that people with 
psychosis are to be feared, considered unpredictable and worthy of ridicule (Pyle & 
Morrison, 2014).  A survey of service users with diagnoses of psychosis across 
fourteen European countries found that 41.7% of respondents had internalised such 
stigmatised beliefs to a moderate or high degree (Brohan, Elgie, Sartorius, 
Thornicroft, & Group, 2010).  Self-stigma has been conceptualised as involving 
three hierarchical concepts: awareness of negative stereotypes about mental health, 
agreement with them and application to the self (Corrigan, Larson, & Ruesch, 2009).  
It is thought that stereotypes are acquired through a process of social learning prior 
to the onset of mental health difficulties, and later become applied to the self when a 
mental health diagnosis is given (Link, Cullen, Struening, Shrout, & Dohrenwend, 
1989).  Research has shown that being labelled with a schizophrenia diagnosis is 
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linked to experiences of public stigma and self-stigma, and having the label may 
even compound the effects of the disorder (Imhoff, 2016; Link et al., 1989).   
 
Cross-sectional research demonstrates that higher levels of self-stigma are linked to 
reductions in: hope (Lysaker, Roe, & Yanos, 2007); self-esteem (Corrigan, Watson, 
& Barr, 2006; Lysaker et al., 2007; Norman, Windell, Lynch, & Manchanda, 2011; 
Yanos, Roe, Markus, & Lysaker, 2015); meaning in life (Hasson-Ohayon et al., 
2014; Or et al., 2013); self-efficacy (Corrigan et al., 2006; Vauth, Kleim, Wirtz, & 
Corrigan, 2007); empowerment (Vauth et al., 2007); personal autonomy (Munoz, 
Sanz, Perez-Santos, & de los Angeles Quiroga, 2011); quality of life (Park, Bennett, 
Couture, & Blanchard, 2013); psychosocial treatment adherence (Tsang, Fung, & 
Chung, 2010); activity levels (Moriarty, Jolley, Callanan, & Garety, 2012); and social 
functioning (Munoz et al., 2011).  A systematic review found moderate to large effect 
sizes for the associations of self-stigma with many of these psychosocial variables 
(Livingston & Boyd, 2010).  Furthermore, there is evidence that service users who 
perceive discrimination by others have greater reliance on avoidant coping 
strategies, such as secrecy and withdrawal (Kleim et al., 2008).  This finding is 
consistent with qualitative research which found that service users may be inclined 
to avoid disclosing their disorder because of fears of negative evaluation and 
rejection from others (Pyle & Morrison, 2014).  Therefore, self-stigma is associated 
with factors that are potentially inconsistent with aspects of personal recovery.  
Interestingly, a recent randomised controlled trial demonstrated that cognitive 
therapy adapted to reappraise self-stigmatising beliefs about psychosis significantly 
improved personal recovery outcomes (Morrison et al., 2016).    
 
Thus, self-stigma may have a negative impact on personal recovery from severe 
mental illness, an association that may be specific to recovery from psychosis - as  
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defined and measured by service users.  However, associations between self-
stigma and clinical recovery may be less clear (Park et al., 2013).  Systematic 
review evidence shows that higher levels of self-stigma were significantly associated 
with increased symptom severity in 50 studies examining the relationships between 
these variables (Livingston & Boyd, 2010).  Notably, the majority of studies included 
in the review did not find significant associations between self-stigma and indices of 
clinical recovery such as number of hospitalisations or functioning (Livingston & 
Boyd, 2010).  In terms of symptomatology, self-stigma has been positively 
associated with positive symptoms, general psychopathology and depression 
(Cavelti, Kvrgic, Beck, Rüsch, & Vauth, 2012; Corrigan et al., 2006; Lysaker et al., 
2007; Park et al., 2013).  While Lysaker et al. (2007) found that increased self-
stigma was also related to greater negative symptoms, other studies report the 
absence of a relationship between self-stigma and negative symptoms (Park et al., 
2013).   
 
The personal recovery literature highlights that, for individuals experiencing mental 
health difficulties, taking ownership of their lives and making their own decisions 
about care and treatment are significant processes in the recovery journey (Leamy 
et al., 2011; Schrank & Slade, 2007).  However, in the current landscape, 
engagement in treatment decisions for service users with diagnoses of psychosis 
centres on issues of ‘capacity’ and ‘consent’; concepts defined within a legal 
context.  In Scotland, a person will have ‘incapacity’ if judged as being incapable of 
acting on, making, understanding, communicating or retaining the memory of 
decisions in order to give or refuse their consent (Scottish Executive, 2000).  A high 
rate of incapacity in people admitted to mental health inpatient units, particularly 
those with a schizophrenia diagnosis (Owen et al., 2008), presents a challenge to 




Research into developing a broader understanding of the factors that may facilitate 
or impede decisional capacity is at a preliminary stage.  Incapacity for treatment 
decisions has predominantly been associated with clinical variables such as a 
diagnosis of psychosis, disorder severity, delusional experiences, psychopathology, 
impaired cognitive abilities, poor insight, involuntary admissions to psychiatric care 
and treatment refusal (Okai et al., 2007; Owen et al., 2009).  Owen et al. (2009) 
found that greater psychopathological symptoms were significantly associated with 
reduced decisional capacity for treatment decisions with a large effect size (hedges 
g=1.07).  A systematic review by Okai et al. (2007) indicated that a small number of 
studies found positive associations between depression and increased decisional 
capacity.  There is, however, little known about the potential influence of 
psychological variables, including self-stigma, on decisional capacity.  Consistent 
with the legal definition, tools developed to assess capacity for treatment decisions 
emphasise understanding and reasoning skills (Mental Welfare Commission for 
Scotland, 2010).  The most researched and well-known is the MacArthur 
Competence Assessment Tool for Treatment (MacCAT-T) (Grisso & Applebaum, 
1998).  Its focus on assessment of cognitive abilities may compromise its utility in 
detecting psychological influences on treatment decision-making, however it is 
currently recommended as the gold standard in decisional capacity research.     
 
It has been highlighted that many people with severe mental health difficulties 
perceive treatment interventions as coercive, whereby they may not fully understand 
the intervention or believe it will benefit them (Corrigan, 2002).  Moreover, perceived 
coercion is often associated with service users not ‘complying’ with their treatment 
(Corrigan, 2002).  Cognitive models suggest that service users with diagnoses of 
psychosis may be less likely to agree they have a need for treatment if doing so 
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activates self-stigmatising beliefs (Morrison, 2001).  This reluctance, in turn, may 
lead to concerns being raised about their ability to make informed decisions about 
their care (Shek, Lyons, & Taylor, 2010), increasing the likelihood of coercive 
treatment and potentially compromising the recovery process.  Indeed, qualitative 
interviews about experiences of treatment decision-making identified that self-stigma 
made it difficult for service users with diagnoses of psychosis to engage in the 
decision-making process, forcing them to assume a passive role in care planning 
(Dunion, & McArthur, 2012; Stovell, Wearden, Morrison, & Hutton, 2016).   
 
Despite these challenges, legislation exists to protect service users’ rights to 
autonomy entitling them to appropriate support to enhance their involvement in 
treatment decisions.  Guidelines have been published recommending ‘supported 
decision-making’ - also referred to as ‘shared decision-making’ - a collaborative 
approach to care and treatment that places significance on service users’ rights, 
preferences and values (Mental Welfare Commission for Scotland, 2016).  Perhaps 
synonymous with the progression from clinical to personal recovery, this approach 
marks a departure from the traditional model of paternalistic healthcare in which 
treatment decisions were based on what healthcare professionals considered to be 
best for the ‘patient’.  Encouragingly, meta-analytic evidence indicates that 
supported decision-making can improve outcomes related to empowerment (Stovell, 
Morrison, Panayiotou, & Hutton, 2016), and thus the approach may fit well with the 
conceptualisation of personal recovery.  However, a greater understanding of the 
factors contributing to effective supported decision-making is needed (Scottish 
Public Services Ombudsman, 2017).  The potential links between subjective 
appraisals of psychosis (i.e. self-stigma) and judgements of decisional capacity have 
yet to be examined.  If they exist, then developing effective strategies to reduce self-
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stigma may have benefits in relation to improving and supporting both decisional 
capacity and personal recovery.   
 
In summary, the existing literature links psychiatric symptoms to personal recovery, 
self-stigma and decisional capacity.  A growing evidence base indicates that self-
stigma may have a negative impact on a number of psychosocial outcomes linked to 
recovery, and a recent RCT signals that overcoming stigmatising beliefs and being 
empowered in one’s own treatment journey leads to recovery outcomes that are 
meaningful to service users (i.e. personal recovery).  However, self-stigma and 
personal recovery have not been investigated in terms of their relationship to 
decisional capacity for treatment.  Thus far, decisional capacity research has 
focused on clinical correlates with little known about the psychological variables that 
that may affect a person’s capacity to be involved in treatment decisions.  
Qualitative data suggests that self-stigma may play a significant role in treatment 
decision-making, but this relationship has not been examined in quantitative 
research.  The present study aims to address this by examining the relationships 
between self-stigma, personal recovery, psychiatric symptoms and decisional 
capacity for treatment.  The following research questions were asked: 
 
1) Is self-stigma significantly associated with symptomatic and personal 
recovery? 
 
2) Is self-stigma significantly associated with decisional capacity for treatment 
decisions? 
 
3) Do self-stigma, personal recovery and psychiatric symptoms predict 









Participants were recruited from community mental health teams and in-patient 
settings across East and South East Scotland, and a voluntary service in South East 
Scotland.  Eligible participants were aged 18-65 years and met International 
Classification of Diseases – tenth revision (ICD-10) (World Health Organisation, 
1992) criteria for schizophrenia, schizoaffective disorder or delusional disorder.  
Participants also had sufficient proficiency in the English language to allow them to 
complete the study measures, and were able to give informed consent to participate 
in research.  Participants were excluded if they had organic impairment, a primary 
diagnosis of substance-induced psychosis, a learning disability or autism spectrum 
disorder, or a current acute relapse of psychotic symptoms.   
 
There was a 12 month window of recruitment into the study over the period August 
2015 to August 2016.  The early phase of recruitment took place in the health board 
in which the researcher was based as a Trainee Clinical Psychologist.  This covered 
a large rural area in South East Scotland with a low population density, in which 
participants received care from generic community mental health teams, or those 
with greater chronicity from a psychiatric rehabilitation service offering inpatient and 
outpatient services.  Participation in the study involved completion of two interview 
protocols and three standardised questionnaires for which there was no payment or 
incentives offered.  These factors presented a challenge to recruiting from a clinical 
population with an already known limited uptake for participation in research.  More 
than half of the study participants (n=15) were recruited from the original recruitment 
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site.  However, on approaching the mid-point of the planned recruitment period, it 
became apparent that the rate of recruitment was unlikely to achieve the sample 
size required to ensure adequate power.  Subsequently, ethical approval was 
sought and granted for recruitment to be extended into two semi-rural health boards 
in East Scotland.  One health board yielded only one further participant due to 
possible saturation of participants with a high volume of research being carried out 
with the target population.  Efforts were therefore focused in the final three months 
of the recruitment period on recruiting from a third health board from which a further 
nine participants completed study measures.  Recruitment seemed to be facilitated 
by referrals being made by clinical psychologists working within a specialist 
psychosis service in which no other research (known to the researcher) was 
ongoing at the time of recruitment.  Challenges were encountered across all three 
recruitment sites with the study measures taking longer to complete than 
anticipated, which meant that the majority of participants were seen on more than 
one occasion to complete the consent form and study measures.  However, this did 
not lead to attrition which suggests that the study was acceptable to participants, 
and highlighted their personal commitment to taking part in this research.             
 
Measures 
Internalised Stigma of Mental Illness Inventory (ISMI) (Ritsher, Otilingham, & 
Grajales, 2003) (Appendix 11) 
 
The ISMI is a 29-item self-report measure that assesses experience of self-stigma 
across five subscales: alienation, stereotype endorsement, discrimination 
experiences, social withdrawal and stigma resistance.  Each item is rated for 
agreement on a 4-point Likert scale ranging from 1=strongly disagree to 4=strongly 
agree.  Total scores or individual scores across each of the subscales can be 
evaluated.  Higher scores indicate increased levels of self-stigma.  The ISMI has 
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been reported to have excellent internal consistency (α = .90) and test-retest 
reliability (α = .92) (Brohan et al., 2010).  In the present study, a high degree of 
internal consistency (Cronbach’s α = .81) was found across the items making up the 
ISMI total score. 
 
Recovery Assessment Scale (RAS) (Giffort, Schmook, Woody, Vollendorf, & 
Gervain, 1995) (Appendix 12) 
 
The RAS is a 41-item self-report measure that assesses service users’ perceptions 
of personal recovery across five subscales: personal confidence and hope; 
willingness to ask for help; goal and success orientation; reliance on others and no 
domination by symptoms.  Each item is rated for agreement on a 5-point Likert scale 
ranging from 1=strongly disagree to 5=strongly agree.  The RAS has been found to 
have good concurrent validity, internal consistency (α = .93) and test-retest reliability 
(r = .88) over a period of fourteen days (Corrigan et al., 1999).  In the present study, 
the internal consistency was good (α = .83).   
 
MacArthur Competence Assessment Tool for Treatment (MacCAT-T) (Grisso, 
Appelbaum, Mulvey, & Fletcher, 1995) (Appendix 13) 
 
The MacCAT-T is a semi-structured interview that offers a standardised method of 
assessing an individual’s competence to make treatment decisions.  The interview 
comprises information being disclosed to participants about their disorder, the 
recommended treatment, its benefits and risks, and an alternative treatment.  For 
the purposes of measuring decisional capacity in the current study, participants 
were given information about a hypothetical research treatment and an alternative, 
and were asked to apply this information to their own situation in order to make a 
decision about which treatment they would choose.  Participants were asked a 
number of questions about their decision-making process so that ratings could be 
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made across four capacities that have been related to decisional capacity: 
understanding disorder and treatment information, appreciation of disorder and 
treatment, reasoning and weighing up consequences, and expressing a choice.  The 
administration and scoring was carried out by the main author in accordance with 
the MacCAT-T manual (Grisso & Appelbaum, 1998).  The MacCAT-T authors 
recommend against calculation of a total score, but ratings can be given on each of 
the four domains as follows: Understanding (0-6); Appreciation (0-4); Reasoning (0-
8); and Expressing a choice (0-2).  Higher scores on the MacCAT-T indicate better 
capacity to make treatment decisions.  The MacCAT-T was selected for use in the 
present study because it is recommended as the best (given that it assesses all four 
abilities related to decision-making) and most researched tool for assessing 
decision-making capacity for treatment decisions (Dunn et al., 2006).  High inter-
rater reliabilities have been reported for each of the subscales in the assessment 
tool (0.99 for understanding, 0.87 for appreciation, 0.91 for reasoning, and 0.97 for 
expressing a choice).  It has also been shown to be a valid and clinically feasible 
measure (Grisso et al., 1997).  
 
Positive and Negative Syndrome Scale (PANSS) (Kay, Flszbein, & Opfer, 1987)  
 
The PANSS was used to establish the level of psychopathology in the sample.  This 
is a semi-structured interview consisting of 30 items to assess participants’ severity 
of symptoms over the preceding seven days.  Severity of symptoms are rated by the 
interviewer on a seven-point Likert scale (1 = absent to 7 = extreme), with higher 
scores indicating greater severity in psychopathology.  In the current study, the 
PANSS was analysed according to the five factor structure validated by van der 
Gaag et al. (2006) which comprises positive symptoms, negative symptoms, 
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cognitive symptoms, excitement and emotional distress.  The internal consistency in 
the present study was excellent (α = .91).   
 
Depression Anxiety Stress Scales – 21 item version (DASS-21) (Lovibond & 
Lovibond, 1995) (Appendix 14) 
 
The DASS-21 is a self-report measure of severity of symptoms of depression, 
anxiety and stress over the seven preceding days.  It has been reported to have 
high internal consistency, ranging from 0.87 to 0.94 in a clinical population (Antony, 
Bieling, Cox, Enns, & Swinson, 1998).  The full 42-item instrument on which it was 
based was reported to have internal consistency in a non-clinical population ranging 
from α = .81 to .91 (Lovibond & Lovibond, 1995).  In the present study, the internal 
consistency was α = .92.  
      
Procedure 
Participants contacted the researcher directly in response to a study poster 
(Appendix 7), or were referred by a member of their care team.  Self-referring 
participants gave verbal consent for the researcher to confirm their suitability for 
inclusion in the study with a member of their care team.  Potential participants 
approached by a member of their care team were offered information about the 
study and given an information leaflet (Appendix 8).  Those who gave verbal 
consent for the researcher to contact them were given a minimum of 24 hours to 
consider the information before the researcher called them by telephone to discuss 
the study and answer any questions.  Those expressing an interest to take part in 
the study met with the researcher at a clinic location or at home.  The study 
measures were commenced once written informed consent was obtained (Appendix 
9).  Participants had the option to have the measures carried out over more than 





An a priori calculation using G*Power3.1 indicated that a sample of 36 participants 
would be required to detect a large effect (f2 = 0.35) in a linear regression analysis of 
three predictor variables (ISMI, PANSS and DASS-21) on decisional capacity 
(MacCAT-T), with a power level of 0.8 and alpha level of 0.05.   
 
Statistical analyses 
Data was analysed using SPSS 21 for Windows.  Kolmogorov-Smirnov tests were 
performed to establish if data were normally distributed.  MacCAT-T domains of 
appreciation and expressing a choice violated the assumption of normality, thus 
were analysed using nonparametric statistical tests.  All other study variables were 
normally distributed and were analysed using parametric tests.  The relationships 
between continuously distributed study variables were examined using correlational 
analyses; and the effect of gender on study variables was examined using 
independent samples t-tests.  Due to the small sample size, bootstrapped 
correlational analyses were also conducted.  Where significant correlations between 
variables were found, linear multiple regression was performed to examine 
prediction of decisional capacity.  Regression analyses were conducted using the 






Sample characteristics and descriptive statistics 
The process of recruitment is displayed in Figure 1.   A total of twenty four 
participants were recruited from two NHS health boards (one rural and one semi-
rural).  Fourteen males (58.3%) and ten females (41.7%) completed study 
measures.  The mean age of the sample was 43.21 years (SD 10.77; range 26-63).  
The primary psychiatric diagnoses of participants were schizophrenia (n=19) and 
schizoaffective disorder (n=5).  The mean duration of illness was 15.83 years (SD 
9.94; range 1-35).  Demographic characteristics of the sample are displayed in 
Table 1. Scores on the ISMI, RAS, DASS-21 and all five PANSS subscales were 
normally distributed, whereas scores on the MacCAT-T appreciation and expressing 
a choice domains were not.  Table 2 reports descriptive statistics for all measures.  
The mean total ISMI score in our sample (mean 2.35, SD 0.44) was similar to that 
found in an American sample of 100 mental health service users with a diagnoses of 
‘serious mental illness’ (mean 2.3, SD 0.4) (Drapalski et al., 2013).  ISMI scores 
greater than 2.5 have been defined as moderate to severe self-stigma, while scores 
in the range of 2.0 – 2.5 have been defined as mild self-stigma (Ritsher & Phelan, 
2004), indicating that our sample fell within the mild self-stigma range.  The mean 
total DASS-21 score was 53.67 (SD 29.16), which compares to 18.38 (SD 18.82) 
obtained from a sample of 1771 members of the general adult UK population 
(Crawford & Henry, 2003).  The mean total understanding score in our sample was 
5.06 (SD 0.45) which indicated better understanding ability than a sample of 40 
inpatients with diagnoses of schizophrenia or schizoaffective disorder  (mean 4.33, 
SD 1.35), but reduced understanding ability compared to a community sample of 40 
people without mental health diagnoses (mean 5.60, SD 0.66) (Grisso & 
Appelbaum, 1998).  The mean total reasoning score in our sample was 5.42 (SD 
1.41), which indicated better reasoning ability than the inpatient sample (mean 5.20, 
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SD 2.42) but reduced reasoning ability compared to the healthy community sample 
(mean 6.15, SD 1.69) (Grisso & Appelbaum, 1998).  Mean scores for the PANSS 
indicated that levels of psychopathology were low to moderate in the sample.  Male 
participants had significantly higher scores than females on the excitement subscale 
of the PANSS (t=2.40, p=.025).  There were no significant gender differences on 
any other study variables.  Participants’ age was also not associated with any study 











Figure 1. Study flow diagram 
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Completed full data set 
(n=24) 
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Table 1. Participant characteristics (n=24) 
Variable             Frequency 
n % 
Gender   
     Male 14 58.3 
     Female 10 41.7 
Ethnicity   
     White British 23 95.8 
     White other 1 4.2 
Relationship status   
     Single 16 66.7 
     Married 2 8.3 
     In a relationship 2 8.3 
     Divorced 4 16.7 
Employment status   
     Employed 2 8.3 
     Unemployed 11 45.8 
     Student 3 12.5 
     Retired 5 20.8 
     Unable to work 3 12.5 
Primary psychiatric diagnosis 
     Schizophrenia 







Medication status   
     Taking antipsychotic medication 24 100 






Table 2. Scores on study measures (n=24) 
 
Variable Range Mean (SD) 
ISMI   
     Total item score 1.41 - 3.00 2.35 (0.44) 
     Total item score without  
     stigma resistance 
1.38 - 3.29 2.44 (0.50) 
     Alienation 1.00 - 3.50 2.57 (0.71) 
     Stereotype endorsement 1.14 - 2.57 1.95 (0.42) 
     Discrimination experiences 1.20 - 3.60 2.69 (0.56) 
     Social withdrawal 1.17 - 4.00 2.68 (0.72) 
     Stigma resistance 1.00 - 2.80 1.94 (0.41) 
RAS   
     Total score     125 - 182 152.46 (14.59) 
     Personal confidence and hope 21 - 39 30.83 (4.92) 
     Willingness to ask for help 3 - 15 11.83 (3.27) 
     Goal and success orientation 13 - 23 19.04 (2.42) 
     Willingness to rely on others 12 - 20 16.33 (2.12) 
     No domination by symptoms 4 - 15 9.38 (2.79) 
DASS-21   
     Total 4 - 106 53.67 (29.16) 
     Depression 0 - 40 19.08 (13.41) 
     Anxiety 2 - 36 15.08 (10.28) 
     Stress 0 - 38 19.50 (10.01) 
MacCAT-T   
     Understanding 3.95 - 6.00 5.06 (0.45) 
     Reasoning 2.00 - 8.00 5.42 (1.41) 
PANSS   
     Total 45 - 107 65.25 (18.18) 
     Positive symptoms 10 - 28 16.54 (5.85) 
     Negative symptoms 7 - 28 14.00 (4.99) 
     Cognitive symptoms 9 - 34 16.54 (6.95) 
     Excitement 4 - 12 6.21 (2.43) 
     Emotional distress 7 - 17 11.96 (2.87) 
 
Note: DASS-21, Depression, Anxiety, Stress Scales – 21 item version; ISMI; Internalised 
Stigma of Mental Illness Inventory; MacCAT-T, MacArthur Competence Assessment Tool for 
Treatment; PANSS, Positive and Negative Syndrome Scale; RAS, Recovery Assessment 






Correlations between study variables are reported in Table 3.  Bootstrapped 
analyses are reported in Appendix 15.  A large and significant correlation was found 
for perceptions of self-stigma and ratings of personal recovery, with higher levels of 
self-stigma associated with reduced recovery (r = -0.533, p = 0.007; Bootstrapped 
95% CI = -0.755 to -0.252).  Higher levels of self-stigma were also significantly 
associated with reduced reasoning ability on the MacCAT-T (r = -0.441, p = 0.031; 
Bootstrapped 95% CI = -0.704 to -0.082), greater negative symptoms (r = 0.501, p = 
0.013; Bootstrapped 95% CI = 0.218 to 0.740), and increased emotional distress as 
measured by the PANSS (r = 0.700, p < .001; Bootstrapped 95% CI = 0.470 to 
0.851) and the DASS-21 (r = 0.601, p = 0.002; Bootstrapped 95% CI = 0.312 to 
0.791).  These associations remained significant when stigma resistance items were 
omitted from the self-stigma variable.   
 
MacCAT-T understanding was significantly correlated with cognitive symptoms (r = -
0.435, p = 0.033; Bootstrapped 95% CI = -0.728 to 0.062) and excitement (r = -
0.573, p = 0.003; Bootstrapped 95% CI = -0.859 to -0.042).  MacCAT-T appreciation 
was significantly associated with positive symptoms (ρ = -0.494, p = 0.014; 
Bootstrapped 95% CI = -0.738 to -0.065), cognitive symptoms (ρ = -0.463, p = 
0.023; Bootstrapped 95% CI = -0.728 to -0.090), reasoning (ρ = 0.435, p = 0.034; 
Bootstrapped 95% CI = 0.019 to 0.724) and expressing a choice (ρ = 0.411, p = 
0.046; Bootstrapped 95% CI = -0.154 to 0.808).  Participants were more likely to 
show appreciation of their disorder and treatment when they had fewer positive and 
cognitive symptoms, while greater appreciation of the disorder and treatment was 




Unexpectedly, personal recovery was not significantly correlated with any other 
study variable other than self-stigma.  Given the size of the correlation between self-
stigma and recovery, partial correlations were conducted to determine if the 
relationships between self-stigma and emotional distress (DASS-21 and PANSS), 
reasoning and negative symptoms remained statistically significant after controlling 
for personal recovery.  Results indicated that, when personal recovery was 
controlled for, the significant association between self-stigma and reasoning ability 
was lost (r = -0.398, p = 0.060) (Table 4).  In contrast, there was no significant 
weakening of the associations of self-stigma with emotional distress on the DASS-
21 (r = 0.511, p = 0.013) or PANSS (r = 0.630, p = 0.001) when personal recovery 
was entered as a control variable, whereas the association between self-stigma and 
negative symptoms became marginally significant (r = 0.411, p = 0.052).  These 
findings suggest that the relationship between self-stigma and reasoning ability is 
accounted for by a person’s level of recovery, whereas emotional distress makes a 
unique contribution to the variance in self-stigma over and above the contribution of 
recovery.  There was a marginally significant trend in the data indicating that 
negative symptoms may also uniquely contribute to self-stigma independently of its 





Table 3. Correlation matrix for all variables included in the analysis 





















-             
ISMI – SR 
 
0.989** -            
RAS 
 
-0.533** -0.506* -           
DASS 
 
 0.601**  0.608** -0.376 -          
MacCAT 
understand 
-0.147 -0.173 -0.040 -0.216 -         
MacCAT  
appreciation 
-0.141 -0.175 -0.097  -0.372  0.281 -        
MacCAT  
reasoning 
-0.441* -0.405*  0.210 -0.248  0.350  0.435* -       
MacCAT  
choice 
-0.131 -0.127 -0.138 -0.200 -0.123  0.411*  0.322 -      
PANSS  
positive 
 0.299  0.322 -0.248 0.710** -0.360 -0.494* -0.160 -0.216 -     
PANSS  
negative 
 0.501*  0.502* -0.323 0.634**  0.031 -0.080 -0.259 -0.167 0.462* -    
PANSS  
cognitive 
 0.251  0.251 -0.189 0.679** -0.435* -0.463* -0.330 -0.284 0.825**  0.473* -   
PANSS 
excitement 
-0.028  0.001 -0.033 0.092 -0.573** -0.111 -0.343 -0.116 0.435* -0.054 0.479* -  
PANSS  
emotion 
 0.700**  0.669** -0.396 0.641** -0.125 -0.167 -0.264  0.086 0.517**  0.584** 0.514* 0.26 - 
Note: DASS, Depression, Anxiety, Stress Scales 21-item version total scores; ISMI, Internalised Stigma for Mental Illness Inventory total mean item scores; ISMI – SR, ISMI total mean item scores 
minus stigma resistance items; RAS, Recovery Assessment Scale total scores; MacCAT understand, MacArthur Competence Assessment Tool for Treatment understanding domain scores; 
MacCAT apprec., MacArthur Competence Assessment Tool for Treatment appreciation domain scores; MacCAT reason, MacArthur Competence Assessment Tool for Treatment reasoning domain 
scores; MacCAT choice, MacArthur Competence Assessment Tool for Treatment expressing a choice domain scores; PANSS positive, Positive and Negative Syndrome Scale positive symptoms 
subscale scores; PANSS negative, Positive and Negative Syndrome Scale negative symptoms subscale scores; PANSS cognitive, Positive and Negative Syndrome Scale cognitive symptoms 
subscale scores; PANSS excitement, Positive and Negative Syndrome Scale excitement subscale scores; PANSS emotion, Positive and Negative Syndrome Scale emotional distress subscale 
scores  *Correlation is significant at the 0.05 level.  **Correlation is significant at the 0.01 level. 
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Table 4. Results of partial correlation controlling for personal recovery total scores 










- 0.986** 0.511** -0.398 0.411* 0.630** 
ISMI – SR 
 
 
















     - 
Note: DASS, Depression, Anxiety, Stress Scales 21-item version total scores; ISMI, Internalised Stigma 
for Mental Illness Inventory total mean item scores; ISMI – SR, ISMI total mean item scores minus stigma 
resistance items; MacCAT reasoning, MacArthur Competence Assessment Tool for Treatment reasoning 
domain scores; PANSS negative, Positive and Negative Syndrome Scale negative symptoms subscale 
scores; PANSS emotion, Positive and Negative Syndrome Scale emotional distress subscale scores. 




Based on the results of the correlational analyses, three linear regression analyses 
were conducted.  Age and gender were entered as predictors in the first blocks, and 
the significant correlates of each of the dependent variables understanding, 
appreciation and reasoning were entered in the second blocks (Table 5).  A post-
hoc calculation of statistical power was conducted based on the equation set out by 
Green (1991): N(8/f2) + (m-1), where f2 = 0.02, 0.15, and 0.35 for small, medium 
and large effects, and m represents the number of predictor variables.  This 
indicated that a sample size of 26 participants provided sufficient power to detect 
large effects in the MacCAT-T understanding, appreciation and reasoning 
regression analyses with 4 predictor variables.  Inspection of the respective 
regression plots, tolerance and VIF statistics indicated that assumptions of 
normality, linearity and homoscedasticity were met (Appendix 16).  Tolerance 
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statistics were >0.2 satisfying the recommendations of Menard (1995), and were 
well above the 0.10 recommended by Tabachnick and Fidell (2013).  As displayed in 
Table 5, linear regression analysis showed that excitement made a significant 
contribution to the prediction of the understanding domain of decisional capacity (β = 
-0.663, p = 0.023).  In contrast, age, gender and cognitive symptoms did not make a 
significant contribution to the model.  Thus, increasing severity of excitement 
symptoms had a negative impact on participants’ understanding of their disorder 
and treatment information.  No significant predictors emerged for the appreciation 
domain of decisional capacity.  There was a marginally significant finding suggesting 
a signal for self-stigma making a unique contribution to the prediction of the 
reasoning domain of decisional capacity (β = -0.482, p = 0.076).  There was no 
indication that age, gender or personal recovery uniquely contributed to the 
prediction of reasoning.         
 
 
Table 5. Regression analyses for decisional capacity domains by predictors 
MacCAT-T 
domain 
Adjusted R2 Predictor β P 
Understanding 0.313 Constant  .000 
Age 0.043 0.847 
Gender -0.326 0.186 
PANSS cognitive symptoms -0.129 0.549 
PANSS excitement -0.663 0.023 
Appreciation 0.240 Constant   .000 
Age 0.102 0.621 
Gender -0.057 0.779 
PANSS cognitive symptoms -0.269 0.438 
PANSS positive symptoms -0.319 0.361 
Reasoning 0.030 Constant  .066 
Age 0.043 0.849 
Gender 0.026 0.908 
Self-stigma (Total ISMI) -0.482 0.076 
Personal recovery (Total RAS) -0.049 0.848 
 Note: ISMI, Internalised Stigma of Mental Illness Inventory; PANSS, Positive and Negative Syndrome 




The current study set out to improve our understanding of the psychological factors 
that may influence decisional capacity and recovery in service users with diagnoses 
of psychosis, focusing on a definition of recovery acceptable to service users.  
Firstly, we examined if self-stigma was associated with both personal recovery and 
symptomatic recovery in our sample, given that previous authors have highlighted 
mixed findings in the empirical literature regarding the latter (Park et al., 2013).  
Secondly, we extended the scope of the current literature, by investigating if a 
relationship existed between service users’ endorsement of self-stigmatising beliefs 
and their capacity to make decisions about their mental health treatment.  Finally, 
we explored if self-stigma, personal recovery and psychiatric symptoms could 
predict service users’ decisional capacity for treatment decisions.  This is pertinent, 
given the emphasis on the role of empowerment in modern conceptualisations of 
recovery, and findings from qualitative research suggesting that self-stigma may 
impede service users’ involvement in treatment decisions (Stovell et al., 2016).       
   
Consistent with previous research (Munoz et al., 2011), the current study found a 
strong, negative association between self-stigma and personal recovery.  This 
highlights that personal and social meanings attached to having a diagnosis of 
psychosis by service users informs their personal adaptation to the disorder.  
Evidence is emerging that the effects of self-stigma on personal recovery may be 
mediated by feelings of hopelessness, shame, and reduced self-esteem (Vass et al., 
2015; Wood, Byrne, Burke, Enache, & Morrison, 2017).  Given this, it was surprising 
that we did not find significant correlations between personal recovery and 




While there was no association with positive symptoms, increased self-stigma was 
significantly associated with greater negative symptoms and emotional distress.  
This is consistent with other studies that have reported significant associations 
between self-stigma and depressed mood (e.g. Ritsher & Phelan, 2004).  
Furthermore, the finding that self-stigma was linked to emotional distress but not 
positive symptoms seems to be synchronous with studies reporting that post-
psychotic depression (PDD) often follows individuals’ recovery from positive 
symptoms, with 50% experiencing PDD following the first episode of psychosis 
(Birchwood, Iqbal, Chadwick, & Trower, 2000).  Relevant to our own findings 
regarding self-stigma, Iqbal, Birchwood, Chadwick, & Trower (2000) found that it 
was the presence of negative appraisals about psychosis, involving loss of social 
status, a sense of entrapment and feelings of shame, that predicted who developed 
PDD.  Similarly, appraising psychosis as uncontrollable and entrapping was 
associated with social anxiety experienced after the first psychotic episode 
(Birchwood et al., 2006).  Given that these effects have been observed following the 
first psychotic episode and soon after diagnosis, it suggests that the endorsement of 
self-stigma may form part of a psychological reaction to the diagnosis itself, leading 
to a pathway of emotional distress (Birchwood, 2003; Birchwood et al, 2000; 
Upthegrove, Marwaha, & Birchwood, 2016).  Indeed, receipt of a diagnostic label 
has been identified as a catalyst for self-stigma, whereby negative stereotypes 
about mental illness, acquired through earlier social learning, become applied to the 
self (Corrigan, 2007; Link et al., 1989).  It has been argued that application of the 
diagnostic label promotes a sense of difference, alienation from those who do not 
have the label, and a loss of social status, while also giving rise to discriminatory 




Thus, receiving a clinical diagnosis seems to provide the context for the activation of 
self-stigma (Wood, Byrne, & Morrison, 2017).  The diagnosis itself can be a source 
of interpersonal threat with service users fearing rejection or devaluation if it 
becomes known to others (Birchwood et al., 2006).   As a result, service users may 
employ maladaptive coping strategies to ‘protect’ themselves from the stigmatising 
label (Link et al., 1989) which may have serious implications for service engagement 
and recovery.  It has been argued that service users with severe mental illness may 
stay away from services or delay help-seeking in order to avoid a stigmatising 
diagnosis (Corrigan, 2004; Corrigan, 2007).  Indeed, a recent systematic review 
found that self-stigma was negatively associated with help-seeking, and was a 
barrier to service users accessing appropriate care (Clement et al., 2015).  Non-
disclosure of disorder, concealment, denial, and social withdrawal were found to be 
strategies used by service users at risk of or experiencing first-episode psychosis to 
avoid negative societal reactions about their disorder (Gronholm, Thornicroft, 
Laurens, & Evans-Lacko, 2017).  Empirical research suggests that having limited 
awareness of the presence of schizophrenia may be adaptive in the context of self-
stigma: Lysaker at al. (2007) found that, for those with schizophrenia spectrum 
disorders who hold self-stigmatising beliefs about mental illness, reduced insight into 
the disorder was associated with greater hope about the future and improved self-
esteem, while better insight seemed to have deleterious effects on hope and self-
esteem.  Interestingly, both the high and low insight groups had significantly fewer 
social relationships than a third group who had high insight but did not endorse self-
stigmatising beliefs about mental illness.  Thus, reduced insight may serve to protect 
self-esteem and hope, but as a safety strategy it is counterproductive for social 
functioning.   
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Contrary to study hypotheses, self-stigma was negatively associated with only the 
reasoning domain of decisional capacity, but not understanding, appreciation or 
expressing a choice in treatment.   The only other significant correlates of decisional 
capacity were psychiatric symptoms: understanding was negatively associated with 
cognitive symptoms and excitement, while appreciation was negatively associated 
with positive symptoms and cognitive symptoms.  In the regression analyses, the 
only significant model that emerged was for PANSS excitement as a predictor of 
understanding.  The excitement factor comprised items including poor impulse 
control, hostility and uncooperativeness.  Therefore, those items may be proxies for 
engagement with treatment, with lower scores on these items implying greater 
engagement with treatment and services (MacBeth, Gumley, Schwannauer, & 
Fisher, 2013).   It may be postulated that if service users understand their disorder 
and treatment then they are more likely to engage in the treatment process.   
 
There was a weak signal (marginally significant) that self-stigma predicted 
reasoning, while there was no effect of recovery contributing to reasoning capacity.   
If replicated in a larger sample, this suggests that service users with lower levels of 
self-stigma may be more able to make comparisons between alternative treatment 
options by weighing up their consequences, including making inferences about how 
different treatment options may affect their everyday life, in order to make a 
treatment decision.  On the contrary, for service users with greater self-stigma, this 
finding may reflect a ‘why try’ effect (Corrigan et al., 2009) whereby they believe that 
their diagnosis means that they are not capable of achieving meaningful outcomes, 
undermining their sense of agency, and preventing them from taking an active role 
in conceptualising the possible benefits and risks of treatment choices on their 
everyday lives in order to make a treatment decision.  Indeed, service users with 
moderate levels of self-stigma and good awareness of their disorder were found to 
96 
 
have increased hopelessness and negative expectations of the future, presenting a 
challenge to their motivation to pursue treatment or recovery goals (Lysaker, Roe & 
Yanos, 2007).   Lysaker, Campbell, & Johannesen (2005) found that when good 
insight into disorder was accompanied by hopelessness, service users tended to 
adopt an avoidant coping style, were less inclined to use problem solving, and were 
more preoccupied with internal distress.       
 
There are several study limitations.  Firstly, the study was underpowered, raising the 
possibility of Type II errors.  That said, the correlational analyses demonstrated 
large effect sizes, thus guiding the decision to perform exploratory regression 
analyses.  However, the regression analyses were likely underpowered to detect 
significant effects.  This was linked to challenges encountered with study 
recruitment, with a limited number of potential participants meeting diagnostic 
criteria in the rural population from which the study recruited, and rates for 
participation in research known to be low for the psychosis population (Honeyman,, 
2014; MacBeth et al., 2015).  The difficulties with recruitment were unfortunate given 
the high rate of informed consent following the information session with the 
researcher and the lack of attrition, indicating that the study had a high acceptability 
with service users. In light of these difficulties, another limitation of the study was 
that levels of psychopathology and self-stigma in the sample were low to moderate, 
which may not be representative of the psychosis population and could limit the 
generalisability of the findings.   
 
A further limitation was the lack of significant associations found between any of the 
decisional capacity domains and personal recovery.  The MacCAT-T is the gold 
standard instrument currently available for assessing decisional capacity.  The 
instrument was designed to detect impairment across four domains of decisional 
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capacity which were developed from a legal framework of competence to give or 
refuse informed consent (Grisso & Appelbaum, 1998).  Previous studies have used 
the MacCAT-T to measure decisional capacity in psychiatric inpatients where 
involuntary admissions to hospital are common and a judgement of incapacity is 
more likely (Okai et al., 2007; Owen et al., 2009).  The participants in the current 
study had only low to moderate levels of psychopathology and mean scores on the 
four decisional capacity domains were higher than has been found for psychiatric 
inpatients (Appelbaum, Grisso, & Hill-Fotouhi, 1997).  It is possible that the findings 
in the current study were vulnerable to a floor effect whereby the MacCAT-T 
instrument was not sensitive to detect changes for participants who did not have 
impaired capacity.  Furthermore, given that the MacCAT-T was operationalised and 
developed for use within a legal context, it is likely to lack precision within 
psychological research to detect significant relationships with complex variables 
such as self-stigma and personal recovery.  It has been pointed out previously that 
the legal conceptualisation of decisional capacity neglects the influence of 
psychological and environmental factors on decision-making (Stovell et al., 2016).  
There is a need for a new measure that will partial out effects of cognitive 
competence, and broaden the construct of capacity to give consideration to the 
psychosocial context of treatment decision-making.        
 
With regard to clinical application, our findings support emotion-focused 
conceptualisations of psychosis, highlighting the role of emotion and negative 
symptoms as predictors of either chronicity or resilience (Freeman & Garety, 2003; 
Gumley, Gillham, Taylor, & Schwannauer, 2013; Smith et al., 2006).  It has been 
pointed out that trials of cognitive behavioural therapy for psychosis have not directly 
targeted depression as a primary outcome (Upthegrove et al., 2016).  The finding 
that self-stigma was not significantly associated with positive symptoms suggests 
98 
 
that current psychological interventions based on single-symptom models of positive 
symptoms may not go far enough to mitigate the effects of self-stigma on emotional 
distress and personal recovery.  However, our findings suggest that adapting these 
models to target self-stigma may be beneficial.  Indeed, a recent pilot randomised 
controlled trial found that adapting cognitive therapy to address self-stigmatising 
beliefs produced significant improvement on personal recovery and depression 
outcomes at post-treatment compared to treatment as usual (Morrison et al., 2016).  
Furthermore, the change from pre-post treatment indicated large effects (d=1.33) of 
the intervention on improving personal recovery.  As this was a pilot trial, the 
findings should be replicated with a larger sample, but these early findings are 
promising.   
 
Consideration of the study findings within the wider empirical literature raises 
implications for services, and highlights the role of the mental health system in 
potentially contributing to or counteracting the effects of self-stigma on psychosis.  
Within current practice, access to mental health care often involves service users 
being ascribed a clinical diagnosis, however this seems to inadvertently compound 
the stigmatising stereotypes of psychosis and activates self-stigmatising beliefs.  
Empirical research into first episode psychosis highlights that individuals are 
required to access services in the context of interpersonal threat and high emotion 
(Birchwood et al., 2006; Iqbal et al., 2000) and are likely to delay help-seeking as a 
safety strategy (Clement et al., 2015).  However, this may give rise to compulsory or 
coercive treatment which is likely to compromise personal recovery.  It is therefore 
important that service providers work with service users to tackle the effects of 
stigma.  One suggestion to mitigate the effects of self-stigma arising from clinical 
diagnosis is a move away from a diagnostic classification system towards a 
dimensional approach that understands mental health difficulties as occurring on a 
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continuum of normal experience (Corrigan, 2007).  A move away from clinical 
diagnosis would counteract the risk of service users being viewed as diagnostic 
groups, and would promote a holistic, person-centred approach to understanding 
service users’ difficulties (Corrigan, 2007).  Adopting a personal recovery model to 
care could also protect against self-stigma, with mental health professionals 
communicating messages of hope and recovery, as opposed to the traditional 
psychiatric view that people with psychosis do not recover (Corrigan, 2007).  
Offering interventions that directly target self-stigma are likely to alleviate emotional 
distress and promote adaptation to illness.  Furthermore, it has been hypothesised 
that negative appraisals and emotional difficulties could be trait markers of 
underlying vulnerability related to social adversity and trauma (Upthegrove et al., 
2016).  Therefore, therapeutic approaches that address the developmental, 
emotional and interpersonal processes underpinning the difficulties experienced in 
psychosis may help to address the challenges of help-seeking and maintain service 
engagement (Gumley et al., 2013).     
 
In summary, mental health services have tended to focus on indices of clinical 
recovery, such as managing psychotic symptoms and reducing risk, as the target of 
treatment (Schrank & Slade, 2007).  However, our findings highlight the need for 
recovery-focused interventions to incorporate consideration of emotion related 
appraisals, and  provide support for service user definitions of recovery which 
highlight that the psychological and social consequences of having a diagnosis can 
be more detrimental than the symptoms of the illness itself (Leamy et al., 2011).  
The cross-sectional design of the current study limits conclusions being drawn about 
the direction of the relationship between self-stigma and emotional distress.  
However, it could be that higher endorsement of self-stigmatising beliefs leads to 
greater levels of distress, or that increased levels of emotional distress make it more 
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difficult for service users to dismiss negative stereotypes.  Longitudinal studies are 
needed to explore these hypotheses, but in either case, the strong relationship 
between these variables supports the argument for clinical interventions to go 
beyond treating the symptoms of illness in order to promote recovery.   
 
There is a consistent pattern emerging from service user research to suggest that 
overcoming stigma, having hope for the future and becoming empowered to make 
one’s own life choices, including those concerning treatment, are integral processes 
of the personal recovery journey (Law & Morrison, 2014; Leamy et al., 2011; 
Schrank & Slade, 2007).  The Mental Welfare Commission has endorsed a move 
towards greater patient involvement in decisions about care and treatment through 
‘supported decision-making’ (Mental Welfare Commission, 2016).  However, 
negative expectations about one’s capabilities and worth arising from self-
stigmatising beliefs are likely to prevent individuals becoming actively involved in 
treatment planning.  Indeed, empowerment and self-stigma have been 
conceptualised as belonging to opposite ends of a continuum (Corrigan, 2002; 
Corrigan, Bink, Schmidt, Jones, & Rüsch, 2015).  It has been argued that not 
involving service users in treatment is likely to reinforce these negative expectations 
and sense of hopelessness (Corrigan, 2002), compounding the problem.  Taken 
with the findings of the current study, this indicates that interventions that aim to 
challenge stigmatising beliefs and support personal empowerment are likely to 
enhance service user engagement and promote recovery.  However, further 
research is needed to provide a clearer picture of the psychosocial influences that 
may promote or hinder treatment engagement, and a fit-for purpose measure of 
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Appendix 2 – PRISMA Checklist 




TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  6 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
7 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  9-10 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
11 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
14 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
13 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
12 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it 
could be repeated.  
12 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 




Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators.  
15 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
15 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis.  
16 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  14 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
12 
 
Page 1 of 2  




Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
44 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
17 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-
up period) and provide the citations.  
25 - 27 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 
12).  
44 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 




Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
N/A 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  44 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression 
[see Item 16]).  
41 - 43 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
46 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
47 - 48 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for 
future research.  
50 - 51 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
N/A 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 
6(7): e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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Appendix 3 – The Cochrane Collaboration Data Collection Form for 
Intervention Reviews: RCTs 
 
 
Cochrane [NAME] Group 
Data collection form for intervention reviews: RCTs only 
Version 3, April 2014 Replace or delete all text in pink. 
Modify as necessary before use. 
 
This form can be used as a guide for developing your own data 
extraction form. Sections can be expanded and added, and irrelevant sections can 
be removed. It is difficult to design a single form that meets the needs of all reviews, 
so it is important to consider carefully the information you need to collect, and 
design your form accordingly. Information included on this form should be 
comprehensive, and may be used in the text of your review, 'Characteristics of 
included studies' table, risk of bias assessment, and statistical analysis. 
Using this form, or an adaptation of it, will help you to meet MECIR standards for 
collecting and reporting information about studies for your review, and analysing 
their results (see MECIR standards C43 to C55; R41 to R45). 
Notes on using data extraction form:  
 Be consistent in the order and style you use to describe the information for 
each report. 
 Record any missing information as unclear or not described, to make it clear 
that the information was not found in the study report(s), not that you forgot 
to extract it.  
 Include any instructions and decision rules on the data collection form, or in 
an accompanying document. It is important to practice using the form and 
give training to any other authors using the form. 
Review title or ID  
Study ID (surname of first author and 
year first full report of study was 
published e.g. Smith 2001) 
 
Report ID  
Report ID of other reports of this study 




Date form completed (dd/mm/yyyy)  
Name/ID of person extracting data  
Reference citation  
Study author contact details  










(Insert inclusion criteria 
for each characteristic as 
defined in the Protocol) 
Eligibility criteria 
met?  
Location in text 
or source (pg & 
¶/fig/table/other) 
Yes No Unclear 
Type of study Randomised controlled 




   
 















   
 





DO NOT PROCEED IF STUDY EXCLUDED FROM REVIEW 
Characteristics of included studies 
Methods 
 Descriptions as stated in report/paper Location in 
text or source 
(pg & 
¶/fig/table/other) 
















or body parts) 
  
Start date   























Include comparative information for each 
intervention or comparison group if 
available 
Location in text 









location and social 
context) 
  
Inclusion criteria    





























exclusions (if not 
provided below by 
outcome) 
  
Age   
Sex   
Race/ethnicity   
Severity of illness   















Copy and paste table for each intervention and comparison group  
Intervention Group 1 
 Description as stated in report/paper Location in text 
or source (pg & 
¶/fig/table/other) 
Group name   
No. randomised to 
group (specify 

























Providers (e.g. no., 
profession, training, 
ethnicity etc. if 
relevant) 
  




changes in other 





staff numbers, cold 
chain, equipment) 
  
Integrity of delivery   






Copy and paste table for each outcome. 
Outcome 1 
 Description as stated in report/paper Location in text 
or source (pg & 
¶/fig/table/other) 




















measurement  (if 
relevant) 
  
Scales: upper and 
lower limits 
(indicate whether 










missing data (e.g. 
assumptions 













power & sample 
size calculation, 





Risk of Bias assessment 
(See Handbook Chapter 8. Additional domains may be added for non-randomised 
studies.) 
Domain Risk of bias Support for judgement 
(include direct quotes where 
available with explanatory 
comments) 
Location in text 
or source (pg & 




















   






   






   






   





   








   






   
  





Data and analysis 
Copy and paste the appropriate table for each outcome, including additional tables 
for each time point and subgroup as required. 
 
Dichotomous outcome  
 Description as stated in report/paper Location in text 
or source (pg & 
¶/fig/table/other) 
Comparison   
Outcome   
Subgroup   
Time point 
(specify from start 
or end of 
intervention) 
  









    
Any other results 
reported (e.g. 
odds ratio, risk 





   
Reasons missing    
No. participants 
moved from other 
group 
   
Reasons moved    
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 Description as stated in report/paper Location in 




Comparison   
Outcome   
Subgroup   
Time point 
(specify from 









































   
Reasons 
missing 





   
Reasons 
moved 





































 Description as stated in report/paper Location in text 
or source (pg & 
¶/fig/table/other) 
Comparison   
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Outcome   
Subgroup   
Time point 
(specify from 
start or end of 
intervention) 
  













    
Overall results SE (or other 
variance) 
  





   
Reasons 
missing 




   
Reasons moved    
































 Description as stated in report/paper Location in 























Assumed risk estimate An estimate of the risk of an event or 
average score without the intervention, 
used in Cochrane 'Summary of findings 
tables'. If a study provides useful 
estimates of the risk or average score 
of different subgroups of the 
population, or an estimate based on a 
representative observational study, you 
may wish to collect this information. 
Bias A systematic error or deviation in 
results or inferences from the truth. In 
studies of the effects of health care, 
the main types of bias arise from 
systematic differences in the groups 
that are compared (selection bias), the 
care that is provided, exposure to other 
factors apart from the intervention of 
interest (performance bias), 
withdrawals or exclusions of people 
entered into a study (attrition bias) or 
how outcomes are assessed (detection 
bias). Reviews of studies may also be 
particularly affected by reporting bias, 
where a biased subset of all the 
relevant data is available. 
Change from baseline A measure for a continuous outcome 
calculated as the difference between 
the baseline score and the post-
intervention score.  
Clusters A group of participants who have been 
allocated to the same intervention arm 
together, as in a cluster-randomised 
trial, e.g. a whole family, town, school 
or patients in a clinic may be allocated 
to the same intervention rather than 
separately allocating each individual to 
different arms. 
Co-morbidities The presence of one or more diseases 
or conditions other than those of 
primary interest. In a study looking at 
treatment for one disease or condition, 
some of the individuals may have other 
diseases or conditions that could affect 
their outcomes. 
Compliance Participant behaviour that abides by 
the recommendations of a doctor, 
other health care provider or study 




Contemporaneous data collection When data are collected at the same 
point(s) in time or covering the same 
time period for each intervention arm in 
a study (that is, historical data are not 
used as a comparison). 
Controlled Before and After Study (CBA) A non-randomised study design where 
a control population of similar 
characteristics and performance as the 
intervention group is identified. Data 
are collected before and after the 
intervention in both the control and 
intervention groups 
Exclusions Participants who were excluded from 
the study or the analysis by the 
investigators. 
Imputation Assuming a value for a measure where 
the true value is not available (e.g. 
assuming last observation carried 
forward for missing participants). 
Integrity of delivery The degree to which the specified 
procedures or components of an 
intervention are delivered as originally 
planned. 
Interrupted Time Series (ITS) A research design that collects 
observations at multiple time points 
before and after an intervention 
(interruption). The design attempts to 
detect whether the intervention has 
had an effect significantly greater than 
the underlying trend. 
Post-intervention The value of an outcome measured at 
some time point following the 
beginning of the intervention (may be 
during or after the intervention period). 
Power In clinical trials, power is the probability 
that a trial will obtain a statistically 
significant result when the true 
intervention effect is a specified size. 
For a given size of effect, studies with 
more participants have greater power. 
Note that power should not be 
considered in the risk of bias 
assessment. 
Providers The person or people responsible for 
delivering an intervention and related 
care, who may or may not require 
specific qualifications (e.g. doctors, 
physiotherapists) or training. 
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Quasi-randomised controlled trial A study in which the method of 
allocating people to intervention arms 
was not random, but was intended to 
produce similar groups when used to 
allocate participants. Quasi-random 
methods include: allocation by the 
person's date of birth, by the day of the 
week or month of the year, by a 
person's medical record number, or 
just allocating every alternate person. 
Reanalysis Additional analysis of a study's results 
by a review author (e.g. to introduce 
adjustment for correlation that was not 
done by the study authors). 
Report ID A unique ID code given to a publication 
or other report of a study by the review 
author (e.g. first author's name and 
year of publication). If a study has 
more than one report (e.g. multiple 
publications or additional unpublished 
data) a separate Report ID can be 
allocated to each to help review 
authors keep track of the source of 
extracted data. 
Sociodemographics Social and demographic information 
about a study or its participants, 
including  economic and cultural 
information, location, age, gender, 
ethnicity, etc. 
Study ID A unique ID code given to an included 
or excluded study by the review author 
(e.g. first author's name and year of 
publication from the main report of the 
study). Although a study may have 
multiple reports or references, it should 
have one single Study ID to help 
review authors keep track of all the 
different sources of information for a 
study. 
Theoretical basis The use of a particular theory (such as 
theories of human behaviour change) 
to design the components and 
implementation of an intervention 
Unit of allocation The unit allocated to an intervention 
arm. In most studies individual 
participants will be allocated, but in 
others it may be individual body parts 
(e.g. different teeth or joints may be 




Unit of analysis The unit used to calculate N in an 
analysis, and for which the result is 
reported. This may be the number of 
individual people, or the number of 
body parts or clusters of people in the 
study. 
Unit of measurement  The unit in which an outcome is 
measured, e.g. height may be 
measured in cm or inches; depression 
may be measured using points on a 
particular scale. 
Validation A process to test and establish that a 
particular measurement tool or scale is 
a good measure of that outcome. 
Withdrawals Participants who voluntarily withdrew 
from participation in a study before the 
completion of outcome measurement. 
 
Sources: 
Cochrane Collaboration Glossary, 2010. Available from www.cochrane.org/glossary. 
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of 
Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 
2011. Available from handbook.cochrane.org. 
Last JM (editor), A Dictionary of Epidemiology, 4th Ed. New York: Oxford University 
Press, 2001. 
Schünemann H, Brożek J, Oxman A, editors. GRADE handbook for grading quality 




Appendix 4 - Reasons for studies excluded (n=119) following full-text 
review 
 
 Authors Year Reason for exclusion 
1 
Ahmed, AO; Hunter, KM; 
Goodrum, NM; Batten, NJ; 
Birgenheir, D; Hardison, E; 
Dixon, T; Buckley, PF 2015 Personal recovery measure not relevant 
2 
Au, DWH; Tsang, HWH; So, 
WWY; Bell, MD; Cheung, V; Yiu, 
MGC; Tam, KL; Lee, GTH 2015 
Intervention not relevant/personal recovery 
not an outcome 
3 
Bartels, SJ; Pratt, SI; Mueser, 
KT; Naslund, JA; Wolfe, RS; 
Santos, M; Xie, HY; Riera, EG 2014 
Less than 50% with psychosis/personal 
recovery not an outcome 
4 
Barton, GR; Hodgekins, J; 
Mugford, M; Jones, PB; 
Croudace, T; Fowler, D 2009 
Secondary analysis of RCT/personal 
recovery not an outcome 
5 
Bechdolf, A; Kohn, D; Knost, B; 
Pukrop, R; Klosterkotter, J 2005 Personal recovery not an outcome 
6 
Beentjes, TAA; van Gaal, BGI; 
Goossens, PJJ; Schoonhoven, L 2016 
Study protocol/personal recovery measure 
not relevant 
7 
Bertelsen et al. (2009) 2009 Personal recovery not an outcome 
8 
Bitter, NA; Roeg, DPK; van 
Nieuwenhuizen, C; van 
Weeghel, J 2015 
Study protocol/personal recovery measure 
not relevant (MHRM) 
9 
Bower, P; Roberts, C; O'Leary, 
N; Callaghan, P; Bee, P; Fraser, 
C; Gibbons, C; Olleveant, N; 
Rogers, A; Davies, L; Drake, R; 
Sanders, C; Meade, O; Grundy, 
A; Walker, L; Cree, L; Berzins, 
K; Brooks, H; Beatty, S; Cahoon, 
P; Rolfe, A; Lovell, K 2015 
Study protocol/personal recovery not an 
outcome (recovery orientation DREEM 
measure) 
10 
Braehler, C; Gumley, A; Harper, 
J; Wallace, S; Norrie, J; Gilbert, 
P 2013 Personal recovery not an outcome 
11 
Cai, CF; Yu, LP; Rong, L; 
Zhong, HL 2014 Personal recovery not an outcome 
12 
Cather, C; Penn, D; Otto, MW; 
Yovel, I; Mueser, KT; Goff, DC 2005 Personal recovery not an outcome 
13 
Chadwick, Paul 2016 Personal recovery not an outcome 
14 
Chan, SWC; Li, ZQ; Klainin-
Yobas, P; Ting, S; Chan, MF; 
Eu, PW 2014 Study protocol/would be eligible 
15 
Chinman, M; Oberman, RS; 
Hanusa, BH; Cohen, AN; 
Salyers, MP; Twamley, EW; 
Young, AS 2015 
Personal recovery measure not relevant 
(MHRM & IMR) 
16 
Compton, MT; Kelley, ME; Pope, 
A; Smith, K; Broussard, B; Reed, 
TA; DiPolito, JA; Druss, BG; Li, 
C; Haynes, NL 2016 





Cook, JA; Copeland, ME; Floyd, 
CB; Jonikas, JA; Hamilton, MM; 
Razzano, L; Carter, TM; 
Hudson, WB; Grey, DD; Boyd, S 2012 Less than 50% with psychosis 
18 
Cook, JA; Copeland, ME; 
Jonikas, JA; Hamilton, MM; 
Razzano, LA; Grey, DD; Floyd, 
CB; Hudson, WB; Macfarlane, 
RT; Carter, TM; Boyd, S 2012 Personal recovery not an outcome 
19 
Cook, JA; Jonikas, JA; Hamilton, 
MM; Goldrick, V; Steigman, PJ; 
Grey, DD; Burke, L; Carter, TM; 
Razzano, LA; Copeland, ME 2013 Fewer than 50% with psychosis 
20 
Cook, JA; Steigman, P; Pickett, 
S; Diehl, S; Fox, A; Shipley, P; 
MacFarlane, R; Grey, DD; 
Burke-Miller, JK 2012 Fewer than 50% with psychosis 
21 
Cook, S; Chambers, E; 
Coleman, JH 2009 Personal recovery not an outcome 
22 
Dalum, HS; Korsbek, L; 
Mikkelsen, JH; Thomsen, K; 
Kistrup, K; Olander, M; Hansen, 
JL; Nordentoft, M; Eplov, LF 2011 
Study protocol/personal recovery measure 
not relevant (IMR & MHRM) 
23 
Davis, LW; Lysaker, PH; 
Kristeller, JL; Salyers, MP; 
Kovach, AC; Woller, S 2015 Personal recovery not an outcome 
24 
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Appendix 5 - Support for risk of bias judgements by rater 1 (HL) 
 
 
Study 1: Barbic 2009 
Domain Judgement Support for judgement 
Sequence generation UNCLEAR Method used to generate the 
allocation sequence not described 
in sufficient detail.    
“...the participants were grouped 
on the basis of which team they 
received ACT services from.  
Next, participants were randomly 
assigned to either the intervention 
or control group”.   
 
Allocation concealment UNCLEAR No description of method to 
conceal the allocation sequence. 
 
Performance bias 
(blinding of participants 
and personnel) 
HIGH All outcomes are self-reported.  
Participants not blinded and 
intervention providers not blinded 
(one study author and another a 
paid member of ACT team in the 
study). 
 
Detection bias (blinding 
of outcome assessment) 
UNCLEAR All outcomes are self-reported 
(hope, empowerment, personal 
recovery, and QoL).  
Participants not blinded, but 
outcome assessors were blinded. 
“Study assessments were 
conducted one week before 
randomization and within three 
days of completion of the 
intervention.  Three assessors, 
who were blind to the treatment 
condition, conducted 
assessments of all study groups”.   
Did not report whether or not 
there were any blind breaks, and 
no description of any attempts to 




UNCLEAR Completeness of outcome data 
unclear - no exclusions or attrition 
reported – not clear how many 
participants/data were lost from 
the study groups, and what the 
reasons for missing data were:  
“In an additional sensitivity 
analysis, missing values for the 
primary outcome measures were 
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replaced by the median of the 
sample”.   
 





UNCLEAR All expected outcomes in the 
methods section are reported as 
planned, but no pre-registered 
study protocol. 
 
Other bias UNCLEAR 81 people identified as meeting 
study eligibility criteria, but only 
33 people (40.7%) agreed to 
randomisation.  No information 




Study 2: Fardig 2011 
Entry Judgement Support for judgement 
Sequence generation LOW “ A computerised random number 
generator was used to assign the 41 
participants who completed the 
baseline assessment and gave 
informed consent to one of the six 
IMR program groups” (pg 607) 
 
Allocation concealment UNCLEAR No description of method to conceal 
the allocation sequence. 
 
Performance bias 







Participants not blinded – intervention 
group would know they received 
treatment in addition to TAU.  
Information given to participants not 
described. 
 
Intervention providers not blinded – 
clinicians delivering the intervention 
would know which participants belong 
to the intervention group. 
 














Clinician-rated IMRS (illness 
management):  
Participants not blinded, assessors 
not blinded 
“participants’ case managers, who 
were not blind to treatment 
assignment, provided ratings on the 





































PECC (psychiatric symptoms): 
“assessments of psychiatric 
symptoms were conducted by trained 
clinicians who were blind to treatment 
assignment”.  Information given to 
participants not described, but 
participants in the IMR group likely to 
be aware they are receiving 
intervention in addition to TAU - not 
blinded.   
Did not report whether or not there 
were any blind breaks, and no 
description of any attempts to counter 
potential blind breaks (e.g. 
participants disclosing to assessors 
which group they had been allocated).   
 
Hospitalisations – no information to 
describe who reviewed medical 
records so unclear if blinded. 
Suicidal ideation in the past week – 
does not say how this was assessed 
and not clear by whom this was 
assessed.   
 
Participant-rated outcome measures 
RAS (41 item)/ MANSA (quality of 
life)/WCQ (ways of coping)  
Information given to participants not 
described, but participants in the IMR 
group likely to be aware they are 
receiving intervention in addition to 
TAU - not blinded. Knowledge of 




LOW All participants completed measures 
at baseline and posttreatment 
19 of the 21 IMR participants 
completed measures at FU 
19 of the 20 TAU participants 
completed measures at FU 
Total attrition 7.3% 
Reasons reported for missing data (1 
participant from each group did not 
respond to a request to schedule the 
FU assessment, and 1 participant in 




UNCLEAR All expected outcomes in the methods 
section are reported as planned, but 




Other bias UNCLEAR Number of people identified as 
meeting study eligibility criteria not 
reported, only the number of 
participants who gave informed 
consent to take part (n=41).  Authors 
state in discussion that recruitment of 





Study 3: Huguelet 2011 
Entry Judgement Support for judgement 
Sequence generation LOW “To ensure random selection, all 
eligible patients of each psychiatrist 
were assigned a random number and 
then listed in numerical order.  Up to 
14 patients per clinician were 
selected…. The first seven patients 
on the numerical list were assigned to 
the intervention group…. The last 
seven patients on the list were 
assigned to the control group, which 
received only standard treatment” 
 




(blinding of participants 
and personnel) 
HIGH Participants and intervention 
providers (psychiatrists) knew group 
allocation - not blinded.  Participants 
in the intervention group received 
additional time with psychiatrists.  
Psychiatrists received supervision 
only for participants in the 
intervention group. Psychiatrists’ 
fidelity to the intervention unclear. 
 
Detection bias (blinding 












Medication Adherence Rating Scale, 
Working Alliance Inventory-Therapist 
Version, PANSS, GAF 
Participants not blinded, assessors 
blinded. 
“Assessment was performed by 
trained psychologists blind to the 
patient’s group assignment”. 
Did not report whether or not there 
were any blind breaks, and no 
description of any attempts to counter 




Participant-rated outcome measures 
RAS 
Participants not blinded, knowledge 




UNCLEAR Attrition and drop-out not reported 





UNCLEAR No pre-registered study protocol.   
 
Other bias UNCLEAR 117 patients recruited but 33 (28%) 
refused to participate.  Information 
about non-participants not collected. 
 
Study 4: Green 2013 
Entry Judgement Support for judgement 
Sequence generation UNCLEAR No description of method used to 
generate allocation sequence. 
“Recruitment was stopped after 38 
eligible persons agreed to attend 
group orientation meetings. Of these, 
32 were enrolled and randomly 
assigned to a cohort” 
 




(blinding of participants 
and personnel) 
HIGH All outcomes are self-reported 
questionnaires 
Intervention providers not blinded and 
participants not blinded.  Delayed 
intervention control group. 
 
Detection bias (blinding 
of outcome assessment) 
 
HIGH 
All outcomes are self-reported 
questionnaires 
CSI, W-QLI, RAS, PAM-MH, BASIS-
24 
Participants not blinded and 
intervention providers not blinded.   





UNCLEAR 28 participants (93%) completed 
questionnaires at FU 1 – the group 
allocation or reasons for the 2 missing 
participants not reported 
30 participants (100%) completed 
questionnaires at FU 2 
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Not reported if there was any missing 
data from the completed 
questionnaires 
Reasons for 2 drop-outs before study 
began not reported 
Analyses not intention to treat 
“…32 were enrolled and randomly 
assigned to a cohort, although two 
persons dropped out before the study 





HIGH No pre-registered study protocol 
Data not reported for all outcomes 
pre-specified in methods section 
 
Other bias UNCLEAR 500 participants had study 
information leaflets mailed to them, 
the first 38 who made contact were 
invited to a study orientation meeting.  
6 did not attend so 32 were 
randomised.   
 
 
Study 5: Morrison 2014 
Entry Judgement Support for judgement 
Sequence generation LOW “Participants were randomly assigned 
electronically (1:1) by a computerised 
system (Open Clinical Data 
Management System [OpenCDMS], 
version 1.7.4) with permuted block sizes 
of four or six, to receive cognitive 
therapy plus treatment as usual, or 




LOW “Because of the variability of TAU, and 
because this control is dependent on 
local service configurations and specific 
sources of referral to the trial, 
randomisation was first stratified by 
study site. OpenCDMS then sent out 
email notifications of the allocations to 
the therapists and trial 
manager…..randomisation was 
independent…..research workers were 







HIGH Participants and intervention providers 



































PANSS & PSYRATS  
“We used many strategies to achieve 
masked ratings: research workers were 
not involved in the randomisation 
process; therapists were required to 
consider room use and diary 
arrangements in view of potential blind 
breaks; and patients were reminded by 
assessors not to talk about treatment 
allocation.  13 blind breaks (representing 
18% of participants) were reported by 
research assistants with a standard 
form: four (31%) of these breaks were 
with TAU and nine (69%) with CT.  In 
cases where concealment was broken, 
another rater assessed the patient for all 
subsequent assessments or the ratings 
were discussed with a masked rater and 
consensus reached.  This assessment 
strategy ensured that only a minority of a 
total of about 500 assessments had their 
validity threatened by absence of rater 
masking”. 
 
Participant-rated outcome measures 
QPR, PSP, BDI-PC & SIAS 
Participants not blinded, knowledge of 




HIGH >25%  
“Missing data rates of 29.7% at primary 




LOW All outcomes are reported as per pre-
registered study protocol. 
 
Other bias UNCLEAR Not all participants offered FU 
assessment for 12, 15 and 18 months 
due to time of entry into study/limited 
funding.  21 out of 143 participants 
referred refused to take part in the study, 
although it is unclear how many would 





Study 6: Salyers 2014 
Entry Judgement Support for judgement 
Sequence generation UNCLEAR No description of method used to 
generate sequence allocation. 
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“A total of 118 participants were 
recruited and randomly assigned to 
either IMR (N=60) or the PS control 
group (N=58)”. 
 




(blinding of participants 
and personnel) 
HIGH Participants and intervention 
providers not blinded to treatment 
allocation. 
 
Detection bias (blinding 












Outcomes assessors blinded to 
participant groups. 
“Participants in both conditions were 
interviewed at baseline, nine months 
and 18 months by trained raters 
blinded to study condition” 
Did not report whether or not there 
were any blind breaks, and no 
description of any attempts to counter 
potential blind breaks. 
 
Participant-rated outcome measures 
RAS 





HIGH Drop-out rate high (>25%) 
IMR group: 15 participants (25%) lost 
at 9 months FU, 22 participants 
(37%) lost at 18 months FU 
PS control group: 17 participants 
(30%) lost a 9 months FU, 24 
participants (42%) lost at 18 months 
FU 
Reasons for drop-out not reported 
 “Intent to treat analyses compared 
changes in IMR and PS groups on 
the outcome measures over time” 
Analysis used “can accommodate 
missing data as well as correlated 
residuals by selecting appropriate 





UNCLEAR All expected outcomes in the 
methods section are reported as 




Other bias UNCLEAR 123 were eligible for study 







Study 7: Jorgensen 2015 
Entry Judgement Support for judgement 
Sequence generation LOW “A statistician with no connection to 
the trial established randomisation. 
An external person packed opaque 
sealed sequentially numbered 
envelopes with the assigned 
treatment” 
 
“Participants were randomized 1:1 in 
blocks of 6 persons”   
 
Allocation concealment LOW “The randomization list was then 
sealed in an opaque envelope that 




(blinding of participants 
and personnel) 
HIGH Participants and intervention 
providers not blinded to treatment 
allocation. 
Same clinicians offering TAU + 
intervention and TAU alone – 
possible crossover effects. 
No. and duration of sessions offered 
to participants in both groups was the 
same – the intervention was included 
in ordinary visits. 
 
 
Detection bias (blinding 

















PANSS subscales, clinician-rated 
clinical insight, GAF-F & GAF-S 
“The first author administered all 
clinician-administered assessments, 
but was blind to participants’ self-
ratings” 
“The first author was trained using a 
series of ‘gold-standard’ videotapes 
and conducted consensus ratings 
with the MHCPs on 10% of the 
PANSS ratings”.  Rater not blinded to 
treatment allocation. 
 





BCIS, IS, RAS, RSES, GAF-S & 
GAF-F 
Participants not blinded, knowledge of 




LOW Low drop-out rate – only 8% total 
drop-out 
5 participants (10% no. randomised) 
in intervention group lost to FU 
3 participants (6% no. randomised) in 
control group lost to FU 
Reported reasons for dropout not 
related to outcome (5/8 reasons 
stated) 
Intention to treat analyses 
“Multiple imputation was applied on 
missing outcome data” 
“Twenty imputations were estimated 




LOW All outcomes are reported as per pre-
registered study protocol. 
 
Other bias UNCLEAR High refusal rate of study 
participation.  204 met eligibility 
criteria, but 103 (50%) refused to take 
part in the study.   
 
 
Study 8: Slade 2015 
Entry Judgement Support for judgement 
Sequence generation LOW Team level: 
“Teams were allocated equally to 
usual treatment plus the REFOCUS 
intervention or to usual treatment 
alone (control), stratified by allocation 
wave to the four SLaM boroughs and 
two 2gether localities to ensure 
balance.  Block randomisation of 
teams was undertaken by the 
independent Mental Health and 
Neuroscience Clinical Trials Unit” 
 
Participant level: 
Report states: “For each team, the 
screened cases of potentially eligible 
patients were randomly ordered, 
according to procedures set out by 
the Mental Health and Neuroscience 
Clinical Trials Unit, and were recruited 




Study protocol states: “In SLaM, two 
randomly ordered lists of service 
users with a psychosis diagnosis on 
the caseload of the team will be 
generated using a random number 
table 
 
Allocation concealment LOW Study protocol states: “All 
randomisation will be undertaken by 
the research team following 
procedures set out by the 
independent Clinical Trials Unit which 
has been awarded full CTU 
registration by UKCRC.  Identifying 
information about teams or service 




(blinding of participants 
and personnel) 
HIGH “Participating staff, patients and 
researchers were aware of allocation 
status” 
 
Study protocol states: “Baseline data 
from staff and service users will as far 
as feasible be collected before 
allocation, to avoid bias based on 
allocation status” 
 
Detection bias (blinding 













Report states “Researchers rated 






Participant-rated outcome measures 
QPR, MANSA, MHCS 
Report states: Data were collected by 
researchers who were trained in all 
measures”.  
Study protocol states: “Follow up data 
will where possible be collected by 
CSOs from the National Institute for 
Health Research Mental Health 
Research Network (MHRN).  This will 









Intervention: 27.1% participants lost 
to follow-up/missing data 
Control condition: 25.4% participants 
lost to follow-up/missing data 
 
Reasons for attrition stated (refused, 
lost contact, too unwell, died) and 
similar across groups – 3 patients 
died in each group, 2 patients had 
missing data from each group 
 
Study protocol states: “All included 
service users will be followed up and 
included in the analysis using 
intention-to-treat approaches, 





LOW All outcomes are reported as per pre-
registered study protocol. 
 
Other bias UNCLEAR High refusal rate for study 
participation. 668 participants met 
eligibility criteria but 265 (40%) 
refused to take part in the study. 
 
 
Study 9: Morrison 2016 
Entry Judgement Support for judgement 
Sequence generation LOW “Participants were randomly assigned 
electronically (1:1) by an 
administrator using the computerised 
system Sealed Envelope with 
permuted block sizes of four, six, and 
eight to receive CT plus TAU and 
monitoring, or to TAU plus 
monitoring.” 
 
Allocation concealment LOW “Email notifications of the allocation 
were sent to trial therapists and the 
trial’s principal investigator.  The trial 
assessor was independent of the 
randomisation process and blind to 
group allocation in order to facilitate 
unbiased rating of a semi-structured 
interview measure of stigma (SIMS: a 
measure developed specifically for 






(blinding of participants 
and personnel) 
HIGH Participants and intervention 
providers knew treatment allocation - 
not blinded. 
 
Detection bias (blinding 

















Personnel measured outcomes 
SIMS 
“The trial assessor was independent 
of the randomisation process and 
blind to group allocation in order to 
facilitate unbiased rating of a semi-
structured interview measure of 
stigma (SIMS: a measure developed 
specifically for this study) at the 
baseline, 4 and 7 month follow-ups.  
Several procedures were used to 
protect the blind: therapists had 
separate office space from the trial 
assessor; therapists and the trial 
assessor were required to consider 
diary arrangements in view of 
potential blind breaks; and 
participants were reminded not to talk 
about treatment allocation with the 
trial assessor.  Two blind breaks 
occurred (7% of the sample), both 
involving participants in TAU and 
were reported using a standard form.”  
 
Participant-rated outcome measures 
QPR-SF, KSS, BDI-7, BHS, SIAS, 
SER-S, ISS 
Participants not blinded, knowledge 




LOW <25%  
“Missing data rates of 10.3% at 4 




UNCLEAR The study protocol was not pre-
registered on a trial registry. 
 
Other bias UNCLEAR 54 participants were referred, 16 
(30%) refused to take part although it 
is unclear how many of these would 
have met the eligibility criteria.  Nine 
who had agreed to assessments of 








Study 10: Schnackenberg 2016 
Entry Judgement Support for judgement 
Sequence generation UNCLEAR Method used to generate the 
allocation sequence not described in 
sufficient detail.    
“Participants were randomised in 
blocks of two (one control group, one 
intervention group).  Thus, where 
possible, every participating MHP had 
one person to support in the 
intervention and one to support in the 
control group, respectively, to 
minimise therapist-specific effects.” 
 
Allocation concealment UNCLEAR No description of method to conceal 
the allocation sequence. 
 
Performance bias 
(blinding of participants 
and personnel) 
HIGH Participants and intervention 
providers knew treatment allocation - 
not blinded. 
 
Detection bias (blinding 


















BPRS-E & PSYRATS auditory 
hallucinations scale 
“Assessments were conducted by the 
respective MHP delivering the 
intervention, as identifying and 
engaging in the full extent of the voice 
hearing experience was best 
considered possible within a trusted, 
non-pathologising relationship.  While 
blinding is difficult to achieve in reality 
as language used might 
unintentionally betray VH group 
allocation, it has the advantage of 
reducing potential raters’ bias and 
social desirability responses by 
participants, as evidenced by lowered 
effect sizes in blinded CBTp trials.  
Given the feasibility focus of this 
study, participant safety and trust 
appeared to outweigh study design 
purity at that stage, and a non-
blinding process was therefore 
chosen.”  
 
Participant-rated outcome measures 
QPR 
Participants and outcome assessors 
not blinded, knowledge of group could 






HIGH Missing data >25%  
 
Analysis was not performed on an ITT 
basis:  “Missing data were followed 
up and a complete case analysis was 
conducted.” 
 
“Only 12 completed all three post-
baseline assessment point measures, 
due to staff shortages (4), staff 
sickness (2), moving house (1), and 
no benefits felt (3 TAU clients).  
Attrition bias was kept low as the 
same number (5) of participants 
respectively in the EFC and TAU 
group did not complete the study.  
This was further supported by 
comparing completers and non-
completers with a series of 
independent t-tests on baseline 





HIGH No pre-registered study protocol. 
Publication indicates that not all pre-
planned outcomes are reported: “As a 
result of the word limit, only clinically 
significant and relevant findings could 
be included in this article” 
 
Other bias UNCLEAR Forty-two VH were screened, 29 met 
inclusion criteria, and 22 finally 
agreed to continue with the study 
following randomisation.  Reasons 
given by the 7 VH not to continue with 
the study following randomisation 
were: (1) a fear of not being 
discharged if they talked about voices 
(n=1); (2) only wanting to take part in 
the opposite groups to the respective 
groups they had been randomised 
into (n=2 and n=1 respectively); (3) 
dying of a heart attack, despite being 
below 30 years of age (n=1); (4) 
focusing on a new relationship 
instead (n=1); (5) no reasons given 














South East Scotland Research  
Ethics Committee 01 
 
Waverley Gate  
2-4 Waterloo Place 
Edinburgh 
EH1 3EG 





Miss Helen Lynch  
Trainee Clinical Psychologist  




Dear Miss Lynch 
 




Enquiries to: Sandra Wyllie 
Extension: 35473  
Direct Line:   0131 465 5473 
Email:  Sandra.Wyllie@nhslothian.scot.nhs.uk 
 
Study title: The role of self-stigma in treatment decision-making  
capacity and recovery in psychosis 
REC reference: 15/SS/0025 
IRAS project ID: 164162 
 
Thank you for your letter of 08 June 2015, responding to the Committee’s request for further 
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Vice-Chair. 
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the date 
of this favourable opinion letter. The expectation is that this information will be published for all 
studies that receive an ethical opinion but should you wish to provide a substitute contact point, 
wish to make a request to defer, or require further information, please contact the REC Manager, 
Mrs Sandra Wyllie, sandra.wyllie@nhslothian.scot.nhs.uk. Under very limited circumstances 
(e.g. for student research which has received an unfavourable opinion), it may be possible to 
grant an exemption to the publication of the study. 
 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below. 
 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
 
Management permission or approval must be obtained from each host organisation prior to 
the start of the study at the site concerned. 
 




Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk. 
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered on 
a publically accessible database. This should be before the first participant is recruited but no later 
than 6 weeks after recruitment of the first participant. 
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment. We will audit the registration details as part of 
the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is registered but 
for non-clinical trials this is not currently mandatory. 
 
If a sponsor wishes to request a deferral for study registration within the required timeframe, 
they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials will 
be registered, however, in exceptional circumstances non registration may be permissible with 
prior agreement from NRES. Guidance on where to register is provided on the HRA website. 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
 




The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of the 





The final list of documents reviewed and approved by the Committee is as follows: 








Document Version Date 
Copies of advertisement materials for research participants [Study 2 03 June 2015 
Poster V.2]    
Covering letter on headed paper [Cover Letter Response to 1 08 June 2015 
Provisional Opinion]    
GP/consultant information sheets or letters [GP Letter V.2] 2 03 June 2015 
    
Interview schedules or topic guides for participants [Positive and 1 27 January 2015 
Negative Syndrome Scale (PANSS)]    
Interview schedules or topic guides for participants [MacArthur 1 27 January 2015 
Competence Assessment Tool for Treatment (MacCAT-T)]    
Interview schedules or topic guides for participants [Interview Guide 1 02 June 2015 
for PANSS V.1]    
Other [Summary CV for Supervisor (Mike Henderson)] 1 30 January 2015 
    
Other [Referrer Information Sheet V.2] 2 22 May 2015 
    
Other [Demographics Form V.1] 1 21 May 2015 
    
Other [Information Collection Card V.1] 1 22 May 2015 
    
Participant consent form [Participant Consent Form V.2] 2 22 May 2015 
    
Participant information sheet (PIS) [Participant Information Sheet 2 22 May 2015 
V.2]    
REC Application Form [REC_Form_27012015]  27 January 2015 
    
Research protocol or project proposal [Study Protocol V.2] 2 21 May 2015 
    
Summary CV for Chief Investigator (CI) [Helen Lynch CV] 1 27 January 2015 
    
Summary CV for supervisor (student research) [Paul Hutton CV] 1 27 January 2015 
    
Validated questionnaire [Internalised Stigma of Mental Illness 2 03 June 2015 
Inventory (ISMI) V.2]    
Validated questionnaire [Recovery Assessment Scale (RAS) V.2] 2 03 June 2015 
    
Validated questionnaire [DASS-21 Questionnaire V.2] 2 03 June 2015 
    
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics 
Committees in the UK. 
 




The attached document “After ethical review – guidance for researchers” gives detailed guidance 
on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 

 Adding new sites and investigators 

 Notification of serious breaches of the protocol 





 Progress and safety reports 

 Notifying the end of the study 









The HRA website also provides guidance on these topics, which is updated in the 





The Health Research Authority is continually striving to provide a high quality service to 
all applicants and sponsors. You are invited to give your view of the service you have 
received and the application procedure. If you wish to make your views known please 





We are pleased to welcome researchers and R&D staff at our training days – 
see details at http://www.hra.nhs.uk/hra-training/ 
 
 
15/SS/0025 Please quote this number on all correspondence 
 



















Enclosures: “After ethical review 
– guidance for researchers” 
 
Copy to: Mrs Jo-Anne Robertson  
















































Do you want to help us understand more about the 
impact of psychosis? 
NHS Borders and the University of Edinburgh are carrying out a study looking at the 
relationship between how a person feels about their mental health condition and the 
treatment they receive in mental health services. 
 
Who can take part? 
People aged 18-65 with a diagnosis of schizophrenia, schizoaffective or delusional disorder. 
 
What will it involve? 
An interview with the researcher and completion of some questionnaires. 
 
If you would like to be emailed an information sheet about the study, or are interested in taking part, 
please contact the researcher, Helen Lynch, Trainee Clinical Psychologist (NHS Borders/University of 





Appendix 8 – Participant Information Sheet  
 
 
       
 
Participant Information Leaflet 
 
 
Study:  Self-stigma, treatment decision-making capacity and recovery  
    in psychosis 
 
Researcher:  Helen Lynch, Trainee Clinical Psychologist 
 
REC Reference Number: 15-SS-0025 
 
 
We would like to invite you to take part in our research study.  Before you 
decide, we would like you to understand why the research is being done and 
what it will involve for you.  Please take time to read the following information 
carefully and discuss it with others if you wish.  If you are interested in the 
study, the researcher will contact you and answer any questions you may 
have before you make your decision.   
 
 
What is the purpose of the study? 
We are interested in studying the relationship between unhelpful beliefs 
people might have about mental health problems, ability to make decisions 
about treatment and recovery from psychosis.   
 
 
Why have I been invited to take part? 
You have been invited to take part because you are aged 18-65, have a 
primary diagnosis of psychosis, and live within the NHS Borders health board 
area.   
 
 
Do I have to take part? 
No - it is completely up to you whether or not you would like to take part.  If 
you are interested, you will be asked for a contact number and a convenient 
time for the researcher to contact you to talk about the study and answer any 
of your questions.  You will be given at least 24 hours to review this 
information leaflet before the researcher makes contact with you.  If you 




you when you will be asked to sign a consent form and only then will we go 
ahead with the study.  You are free to not take part or to stop taking part at 
any point in the study, without giving a reason.  Whatever you decide, your 
normal care will not be affected.   
 
What will taking part involve? 
We expect that your participation in the study could last up to two and a half 
hours.  You may choose to have this carried out over more than one 
occasion.   
 
The researcher will ask you some questions about mental health problems.  
There will be an interview and some questionnaires focused on: 
 
 Your own experience of mental health problems. 
 Your views about mental health problems. 
 Your ability to make decisions about treatment. 
 
If you have any difficulties with reading then the researcher will read the 
questionnaires out to you.  The researcher will ask your permission to make 
an audio recording so that the interview can be listened to by the researcher 
and scored.     
 
You can have breaks during the interview as and when you want them.  You 
can choose to stop taking part or postpone the interview to another day. 
 
 
Where will it be held? 
We will be able to meet you at your local Community Mental Health Team 
(CMHT) base, GP surgery or hospital.  We will meet you wherever is easiest 
for you.  We may be able to visit you at home if you are not able to travel.  If 
you wish to be seen at home, before coming to visit you, we will need your 
consent for your mental health care team to share with us any necessary 
information about risk that may be held on your file.     
 
 
What happens next? 
After the study, we will give you time to ask any questions and talk about 
what it was like for you taking part.  You will be offered the choice to receive 
a summary of the study’s findings that will be produced once the study is 
finished in May 2016.  You can also choose to review and contribute to this 




Once we have your permission, we will inform your care team and GP that 
you are taking part in the study.  Information collected about you during the 
study will not be fed back or exchanged unless you ask us to.  The only time 




something that gave the researcher concerns about your or others’ safety, in 
order to keep you and others safe.  The researcher would discuss this with 
you at the time if this happens.  If you have any questions about this, please 




What will happen to my data? 
Your name and contact details will be stored securely by the researcher in a 
locked cabinet on NHS premises and then destroyed once the study is 
finished in May 2016.  The data we collect from you during the study will be 
anonymised.  It will be stored in an encrypted (i.e. scrambled) format on an 
NHS computer for the duration of the study, and afterwards at the University 
of Edinburgh.  You can ask for your data to be removed from the study until 
the point that the results are published.  After this time it will not be possible 
to remove your data from the study.  The results from this study are likely to 
be published in scientific journals and used in presentations with the wider 
research and NHS communities.  However, as the data will be anonymised 
you will not be able to be identified.  Your results from the study will therefore 
remain confidential.       
 
Your data and consent form may be examined by responsible individuals 
who carry out audits in the NHS.  This is usual practice to make sure that 
research is being carried out responsibly.  With this exception, your data will 
only ever be made available to the research team. 
 
 
What are the benefits and disadvantages to me of taking part? 
Your participation and feedback will help us understand better how beliefs 
about mental illness may affect a person’s involvement in their treatment and 
recovery from psychosis.  This could help to improve how we provide mental 
health services in the future.  Taking part is unlikely to benefit you directly, 
however you can ask for your assessment information to be shared with your 
care team to help clarify your care needs.  
 
It is possible that you may find the interview and questionnaires tiring.  We 
might ask you things that you find upsetting (e.g. mental health problems). 
You will be free to stop the interview at any point.  You can have as many 
short breaks as you need or split the testing over two dates if you prefer. 
 
 
What if I need emotional support following the study? 
If you feel you need listening and emotional support, you may wish to contact 
the free, confidential helplines listed below:  
  
Samaritans  
24 hour support. 




Textphone: 08457 90 91 92 




Tel: 0800 83 85 87  
Website: http://www.breathingspacescotland.co.uk/ 
Borderline 
Local mental health helpline offering an emotional support and listening 
service. 
Tel: 0800 027 4466 
If you notice a significant decline in your mental health following your 
participation in the study we would recommend that you contact your GP. 
 
 
Expenses and payments 
We will refund your travel expenses if you drive or use public transport to 
travel from your home to take part in the study.  Please keep your receipts for 
this journey if you do travel by public transport.  For more information about 
this, please contact the researcher.  Please note that it could take up to a 
month to receive your reimbursement.   
 
We are unable to offer any payments to people for taking part. 
 
 
Who is organising and funding the study? 
The research has been designed and is being carried out by a Trainee 
Clinical Psychologist undertaking a Doctorate in Clinical Psychology at the 
University of Edinburgh.  The study is being supervised by Dr Paul Hutton 
(Clinical Psychologist, University of Edinburgh) and Mr Mike Henderson 
(Consultant Clinical Psychologist, NHS Borders).  Funding and sponsorship 
has been provided by the University of Edinburgh. 
 
 
Who has reviewed the study? 
This study has been reviewed and approved by a NHS Ethics Committee and 
NHS Borders Research and Development. 
 
 
Who can I contact if I have a complaint? 
You are free to discuss any concerns about the study with the researcher 
(contact details at the end of this leaflet) who will do her best to assist you. If 






NHS Borders Feedback and Complaints Team 
Borders General Hospital 
Melrose TD6 9BS 
Email: complaints.clingov@borders.scot.nhs.uk 
Telephone: 01896 826719 
In the unlikely event that something goes wrong and you are harmed during 
the research and this is due to someone‘s negligence then you may have 
grounds for a legal action for compensation against the relevant NHS 
organisation but you may have to pay your legal costs. The normal National 
Health Service complaints mechanisms will still be available to you.   
 
 
Who can I contact about this study? 
If you would like any further information about the study or think you might 
like to take part, please contact the researcher: 
 
 Helen Lynch, Trainee Clinical Psychologist, NHS Borders 
 Email:  helenlynch2@nhs.net 
 Work mobile:  07775 227 129  
 
If you prefer, you can ask a member of your care team to contact the 
researcher on your behalf. 
 
You are also free to discuss the study or any issues around participating in 
research with the study’s supervisors.  Dr Paul Hutton (Clinical Psychologist, 
University of Edinburgh) can be contacted on 0131 651 3972, and Mr Mike 
Henderson (Consultant Clinical Psychologist, NHS Borders) on 01896 
827151. 
 
If you would prefer to speak to someone who is not a member of the 
research team but who can answer questions more generally about taking 
part in research, please contact Joy Borowska (Research Governance Co-
ordinator, NHS Borders) on 01896 826717. 
 
 






Appendix 9 – Participant Consent Form  
 
          
 
Study Number: 15-SS-0025 




Title of Project:   The role of self-stigma in treatment decision-making capacity and recovery in 
psychosis 
Lead Researcher:   Helen Lynch, Trainee Clinical Psychologist 
Please initial box  
1. I confirm that I have read the Participant Information Leaflet dated 22/05/2015 (Version 2)  
for the above study. I have had the opportunity to consider the information, ask questions and  
have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I agree to my General Practitioner and/or mental health care team being informed of my  
 participation in the study. 
 
4. I understand that relevant sections of data collected during the study may be looked at by  
individuals from the regulatory authorities and from the Sponsor(s) (NHS Lothian and the  
University of Edinburgh) or from the other NHS Board(s) where it is relevant to my taking  
part in this research. I give permission for those individuals to have access to my records. 
 
5. All the information I provide in the study will be anonymous and confidential.  However, I  
understand that if I reveal information about future harm to myself, or others, that information  





6. If wishing to be seen at home, I agree that my care team can share with the researcher  
information from the risk assessment that is held in my patient file.  
 
7. I agree to being audio recorded as part of the study.  
 
 







            
Name of Participant  Date    Signature 
 
 
            
















Age:  _________________  Gender: (please circle) Male  /  Female 
 
 
What is your relationship status? (please circle) 
 




Please provide the first part plus one digit of your postcode: 





What is your ethnic group? Please tick the box most relevant to you 
 
 
 White British 
 White other 
 Asian British 




Employment status: (please circle) 
 
 
Employed  /  Unemployed  /  Student  /  Retired  /   
 












Thank you for taking the time to complete this form. 
  
 Black British 
 Black other 














Participant No: ____________    Date:______________ 
 
 
We are going to use the term “mental illness” in the rest of this questionnaire, but 
please think of it as whatever you feel is the best term for it. 
 
For each question, please mark whether you strongly disagree (1), disagree (2), 





Disagree Agree Strongly 
Agree 
 
1. I feel out of place in the world 
because I have a mental illness. 
 
1 2 3 4 
2. Mentally ill people tend to be 
violent. 
 
1 2 3 4 
3. People discriminate against me 
because I have a mental illness. 
 
1 2 3 4 
4. I avoid getting close to people 
who don’t have a mental illness 
to avoid rejection. 
 
1 2 3 4 
5. I am embarrassed or ashamed 
that I have a mental illness.  
 
1 2 3 4 
6. Mentally ill people shouldn’t get 
married. 
 
1 2 3 4 
7. People with mental illness make 
important contributions to society. 
 
1 2 3 4 
8. I feel inferior to others who don’t 
have a mental illness. 
 
1 2 3 4 
9. I don’t socialise as much as I 
used to because my mental 
illness might make me look or 
behave “weird.” 




     
 Strongly 
Disagree 
Disagree Agree Strongly 
Agree 
10. People with mental illness cannot 
live a good, rewarding life. 
 
1 2 3 4 
11. I don’t talk about myself much 
because I don’t want to burden 
others with my mental illness.  
 
1 2 3 4 
12. Negative stereotypes about 
mental illness keep me isolated 
from the “normal” world. 
 
1 2 3 4 
13. Being around people who don’t 
have a mental illness makes me 
feel out of place or inadequate. 
 
1 2 3 4 
14. I feel comfortable being seen in 
public with an obviously mentally 
ill person. 
 
1 2 3 4 
15. People often patronise me, or 
treat me like a child, just because 
I have a mental illness. 
 
1 2 3 4 
16. I am disappointed in myself for 
having a mental illness. 
 
1 2 3 4 
17. Having a mental illness has 
spoiled my life. 
 
1 2 3 4 
18. People can tell that I have a 
mental illness by the way that I 
look.  
 
1 2 3 4 
19. Because I have a mental illness, I 
need others to make most 
decisions for me. 
 
1 2 3 4 
20. I stay away from social situations 
in order to protect my family or 
friends from embarrassment. 
 
1 2 3 4 
21. People without mental illness 
could not possibly understand 
me. 











Disagree Agree Strongly 
Agree 
22. People ignore me or take me less 
seriously just because I have a 
mental illness. 
 
1 2 3 4 
23. I can’t contribute anything to 
society because I have a mental 
illness. 
 
1 2 3 4 
24. Living with mental illness has 
made me a tough survivor. 
 
1 2 3 4 
25. Nobody would be interested in 
getting close to me because I 
have a mental illness. 
 
1 2 3 4 
26. In general, I am able to live my 
life the way I want to. 
 
1 2 3 4 
27. I can have a good, fulfilling life, 
despite my mental illness. 
 
1 2 3 4 
28. Others think that I can’t achieve 
much in life because I have a 
mental illness. 
 
1 2 3 4 
29. Stereotypes about the mentally ill 
apply to me. 
 
1 2 3 4 
 







Appendix 12 - Recovery Assessment Scale (RAS) (Giffort et al., 1995) 
 
Recovery Assessment Scale 
 
 
Participant ID No:____________   Date:______________ 
 
 
Instructions:  Below is a list of statements that describe how people sometimes feel 
about themselves and their lives.  Please read each one carefully and circle the 
number to the right that best describes the extent to which you agree or disagree 










1.  I have a desire to 
succeed 
 
1 2 3 4 5 
2. I have my own plan for 
how to stay or become 
well 
 
1 2 3 4 5 
3. I have goals in my life 
that I want to reach 
 
1 2 3 4 5 
4. I believe I can meet my 
current personal goals 
 
1 2 3 4 5 
5. I have a purpose in life 
 
1 2 3 4 5 
6. Even when I don’t care 
about myself, other 
people do 
 
1 2 3 4 5 
7. I understand how to 
control the symptoms of 
my mental illness 
 
1 2 3 4 5 
8. I can handle it if I get sick 
again 
 
1 2 3 4 5 
9. I can identify what 
triggers the symptoms of 
my mental illness 
 
1 2 3 4 5 
10. I can help myself become 
better 










11. Fear doesn’t stop me 
from living the way I want 
to 
 
1 2 3 4 5 
12. I know that there are 
mental health services 
that do help me 
 
1 2 3 4 5 
13. There are things that I 
can do that help me deal 
with unwanted symptoms 
 
1 2 3 4 5 
14. I can handle what 
happens in my life 
 
1 2 3 4 5 
15. I like myself 
 
1 2 3 4 5 
16. If people really knew me, 
they would like me 
 
1 2 3 4 5 
17. I am a better person than 
before my experience 
with mental illness 
 
1 2 3 4 5 
18. Although my symptoms 
may get worse, I know I 
can handle it 
 
1 2 3 4 5 
19. If I keep trying, I will 
continue to get better 
 
1 2 3 4 5 
20. I have an idea of who I 
want to become 
 
1 2 3 4 5 
21. Things happen for a 
reason 
 
1 2 3 4 5 
22. Something good will 
eventually happen 
 
1 2 3 4 5 
23. I am the person most 
responsible for my own 
improvement 
 
1 2 3 4 5 
24. I’m hopeful about the 
future 
 










25. I continue to have new 
interests 
 
1 2 3 4 5 
26. It is important to have fun 
 
1 2 3 4 5 
27. Coping with my mental 
illness is no longer the 
main focus of my life  
 
1 2 3 4 5 
28. My symptoms interfere 
less and less with my life 
 
1 2 3 4 5 
29. My symptoms seem to be 
a problem for shorter 
periods of time each time 
they occur 
 
1 2 3 4 5 
30. I know when to ask for 
help 
 
1 2 3 4 5 
31. I am willing to ask for 
help 
 
1 2 3 4 5 
32. I ask for help, when I 
need it 
 
1 2 3 4 5 
33. Being able to work is 
important to me 
 
1 2 3 4 5 
34. I know what helps me get 
better 
 
1 2 3 4 5 
35. I can learn from my 
mistakes 
 
1 2 3 4 5 
36. I can handle stress 
 
1 2 3 4 5 
37. I have people I can count 
on 
 
1 2 3 4 5 
38. I can identify the early 
warning signs of 
becoming sick 
 
1 2 3 4 5 
39. Even when I don’t believe 
in myself, other people do 
 




40. It is important to have a 
variety of friends 







41. It is important to have 
healthy habits 
 
1 2 3 4 5 
 







Appendix 13 – MacArthur Competence Assessment Tool for Treatment 
(MacCAT-T) (Grisso et al., 1995) Interview Schedule 
 
I am going to ask you some questions about a possible, hypothetical treatment. This 
discussion is just for the purpose of this interview and will not affect your actual treatment. 
First, I will describe to you what I believe is the problem. Then I’ll talk to you about the 
research treatment, and the possible risks and benefits. I will ask you to apply that 
information to yourself, and then I’ll ask you to make a decision about whether you would or 







· Diagnosis  
 
· Feature of disorder  
 
· Feature of disorder  
 
· Feature of disorder  
 
· Course of disorder  
 
Now please explain in your own words what I’ve said about your condition. 
 






Now that is what I think is the problem in your case. If you have any reason to doubt that, I’d 








1. Name of treatment: Medicine 1  
 
2. Feature of treatment: It can be taken as tablets or liquids twice a day  
 
3. Feature of treatment: You will start at a low dose and increase until we find the right 
dose for you.  
 
4. Feature of treatment: You ought to stay on the medication for at least 2 years and see 
your doctor once a month  
 










1. Benefit: It will make your symptoms less troublesome  
 
2. Benefit: It will reduce the risk of relapse. With treatment 15% relapse. Without 
treatment 57% relapse  
 
3. Risk: There is a low risk that you may experience problems such as abnormal 
movements of your mouth and tongue, which you cannot control.  
 
4. Risk: There is a moderate risk that you may experience problems with weight gain  
 
Now please explain in your own words what I’ve said about benefits and risks of this 
treatment. 
 







You might or might not decide that this is the treatment you want – we’ll talk about it later. 
But do you think it’s possible that this treatment might be of some benefit to you? 
 
So you feel that it is / isn’t possible for this treatment to be of some help for your condition. 
Can you explain that to me? What makes it seem that the treatment would  








1. Name of treatment: No treatment  
 
2. Feature of treatment: You do not have to take any tablets  
 
3. Feature of treatment: You will need to continue seeing a doctor or nurse or 
psychologist every month  
 
4. Feature of treatment: You ought to continue attending the service for at least 2 years  
 
Now please explain in your own words what I’ve said about this treatment 
 









2. Benefit: There is no risk of weight gain.  
 
3. Risk:  The likelihood is your symptoms will continue without treatment  
 
4. Risk: There is a high risk of relapse. Without treatment 57% of patients relapse 
within a year.  
 
 
Now please explain in your own words what I’ve said about benefits and risks of this 
treatment. 
 
Re-disclose and re-enquire if necessary. 
 
 
First choice and reasoning 
 
Now let’s review the choices that you have. First ....: second..... Which of these seems 
best for you? Which do you think you would be most likely to want? 
 
You think that (state patient’s choice) might be best. Tell me what it is that makes that 
seem better than the others. 
 





I told you about some of the possible benefits and risks or discomforts of (name the patient’s 
preferred treatment option). What are some ways that these might influence your everyday 
activities at home or at work? 
 
Now let’s consider (no-treatment option). What are some ways that the outcomes of that 





When we started this discussion you favoured (insert First Choice from earlier enquiry, or 
note that the patient seemed to be having difficulty deciding). What do you think now that 











Appendix 14 - Depression Anxiety Stress Scales - 21 Item Version (DASS-21, 
Lovibond & Lovibond, 1995) 
 
DAS S 21 Participant No: Date: 
 
Please read each statement and circle a number 0, 1, 2 or 3 which indicates how much the statement 
applied to you over the past week.  There are no right or wrong answers.  Do not spend too much time 
on any statement. 
 
The rating scale is as follows: 
0  Did not apply to me at all 
1  Applied to me to some degree, or some of the time 
2  Applied to me to a considerable degree, or a good part of time 
3  Applied to me very much, or most of the time 
 
1 I found it hard to wind down 0      1      2      3 
2 I was aware of dryness of my mouth 0      1      2      3 
3 I couldn't seem to experience any positive feeling at all 0      1      2      3 
4 I experienced breathing difficulty (eg, excessively rapid breathing, 
breathlessness in the absence of physical exertion) 
0      1      2      3 
5 I found it difficult to work up the initiative to do things 0      1      2      3 
6 I tended to over-react to situations 0      1      2      3 
7 I experienced trembling (eg, in the hands) 0      1      2      3 
8 I felt that I was using a lot of nervous energy 0      1      2      3 
9 I was worried about situations in which I might panic and make 
a fool of myself 
0      1      2      3 
10 I felt that I had nothing to look forward to 0      1      2      3 
11 I found myself getting agitated 0      1      2      3 
12 I found it difficult to relax 0      1      2      3 
13 I felt down-hearted and blue 0      1      2      3 
14 I was intolerant of anything that kept me from getting on with 
what I was doing 
0      1      2      3 
15 I felt I was close to panic 0      1      2      3 
16 I was unable to become enthusiastic about anything 0      1      2      3 
17 I felt I wasn't worth much as a person 0      1      2      3 
18 I felt that I was rather touchy 0      1      2      3 
19 I was aware of the action of my heart in the absence of physical 
exertion (eg, sense of heart rate increase, heart missing a beat) 




20 I felt scared without any good reason 0      1      2      3 





Appendix 15 – Bootstrapped 95% confidence intervals (CI) for all variables included in the analysis 
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 0.298  
0.830** 























































































Note: DASS, Depression, Anxiety, Stress Scales 21-item version total scores; ISMI, Internalised Stigma for Mental Illness Inventory total mean item scores; ISMI – SR, ISMI total mean item scores 
minus stigma resistance items; RAS, Recovery Assessment Scale total scores; MacCAT understand, MacArthur Competence Assessment Tool for Treatment understanding domain scores; 
MacCAT apprec., MacArthur Competence Assessment Tool for Treatment appreciation domain scores; MacCAT reason, MacArthur Competence Assessment Tool for Treatment reasoning domain 
scores; MacCAT choice, MacArthur Competence Assessment Tool for Treatment expressing a choice domain scores; PANSS positive, Positive and Negative Syndrome Scale positive symptoms 
subscale scores; PANSS negative, Positive and Negative Syndrome Scale negative symptoms subscale scores; PANSS cognitive, Positive and Negative Syndrome Scale cognitive symptoms 
subscale scores; PANSS excitement, Positive and Negative Syndrome Scale excitement subscale scores; PANSS emotion, Positive and Negative Syndrome Scale emotional distress subscale 
scores.*Correlation is significant at the 0.05 level.  **Correlation is significant at the 0.01 level.  a Unless otherwise noted, bootstrap results are based on 1000 
bootstrap samples b Based on 971 samples
180 
 
Appendix 16 – Collinearity statistics for decisional capacity domains by predictor 
 
 
MacCAT-T domain Predictor Collinearity statistics 
Tolerance VIF 
Understanding Age 0.621 1.610 
Gender 0.528 1.895 
PANSS cognitive symptoms 0.671 1.489 
PANSS excitement 0.419 2.384 
Appreciation Age 0.596 1.678 
Gender 0.528 1.895 
PANSS cognitive symptoms 0.285 3.512 
PANSS excitement 0.413 2.419 
PANSS positive symptoms 0.300 3.333 
Reasoning Age 0.834 1.199 
Gender 0.855 1.169 
Self-stigma (Total ISMI) 0.642 1.556 
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